Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (364 reviews)

For research use only.

Catalog No.S1047 Synonyms: MK0683

364 publications

CAS No. 149647-78-9

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Selleck's Vorinostat (SAHA) has been cited by 364 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001364

PubMed: 33173727 ( click the link to review the publication )

Sci Adv, 2020, 6(33):eaba6617

PubMed: 32851167 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(2)e001037

PubMed: 33158915 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )
Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Andrology, 2020, 10.1111/andr.12922

PubMed: 33064925 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )
Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01394-w

PubMed: 32709923 ( click the link to review the publication )

Viruses, 2020, 12(10)E1067

PubMed: 32977702 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Biomater Sci, 2020, 10.1039/d0bm00119h

PubMed: 32706009 ( click the link to review the publication )

Cell Cycle, 2020, 1-16

PubMed: 32807015 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 13(11)E345

PubMed: 33121173 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Int J Cancer, 2019, 145(9):2496-2508

PubMed: 30963560 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )
Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )
NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Cancer Biol Ther, 2019,

PubMed: 30142009 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )
Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Oncoimmunology, 2018,

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2520-2531

PubMed: 29917299 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )
Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2017,

PubMed: 28673995 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Mol Ther Oncolytics, 2017,

PubMed: 28812060 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(2):374-386

PubMed: 27488871 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )
Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )
Oncoimmunology, 2016,

PubMed: 27471639 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

Biol Chem, 2016,

PubMed: 26431101 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )
Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )
Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0130339

PubMed: 26091518 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139740

PubMed: 26466379 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143897

PubMed: 26623653 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )
Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )
FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5637-50

PubMed: 25026298 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )
Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )
J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40684

PubMed: 22808232 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(6):e21382

PubMed: 21738649 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )
BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MYPLbY5ie2ViQYPzZZk>		NVTl[4d7OSCq	NFvBdZVFVVOR	Mny5ZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	MoT3NVE6PjB2OEm=
Friend leukemic cell	NVT5bIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkG5OVAh\|ryP	NVHGfm5SPzJiaB?=	NHztZ3FFVVOR	MmKyTWM2OD1yLkm5JO69VQ>?	MkG2NVIyODl7MUO=
K562	NWHp[IxyU2mwYYPlJGF{e2G7		M1q2U\|YhcA>?	NEPVZWJFVVOR	NWT0Z\|l{UW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIDjtbZh1fXKnIH;mJGhFSUNzIHHu[EBJTEGFMjmge4l1cCCLQ{WwJI9nKDBwMEGg{txO	MoLPNVI1OTl\|OEC=
HT1080	NHqzfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoD3O\|IhcA>?	MVzEUXNQ	NVHwRYpEUUN3ME2yMlQh\|ryP	NUTxS2RqOTJ{N{CxO\|U>
H1299	Mmm2T4lv[XOnIFHzd4F6		MUKyNEBucW5?	MWPEUXNQ	NWLnOpF4UW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0>	MYqxOFUzOTR{Mh?=
H1299	M{njS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXzjV4dyPzJiaB?=	M3jhdWROW09?	MVzJR\|UxRTdwMkSg{txO	NXLzVYt1OTR3MkG0NlI>
HeLa	MXzLbY5ie2ViQYPzZZk>		M36zO\|MxKG2rbh?=		MWHJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	MmDiNVU3ODN7NEm=
LOX-IMVI	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1LtdVQ5KGh?		M1HDeGlEPTB;MT6zJO69VQ>?	MVuxOVcyPTR5MB?=
NCI-H226	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\5TlQ5KGh?		MmezTWM2OD1{Lk[g{txO	MlLoNVU4OTV2N{C=
RXF-631L	NID6b4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEH4cnc1QCCq		MXjJR\|UxRTJizszN	M{GwUlE2PzF3NEew
SNB-78	NWfQSpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUKzeI5wPDhiaB?=		MYLJR\|UxRTF4IN88US=>	NHTXVIgyPTdzNUS3NC=>
St-4	M1H3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFPSe4Y1QCCq		MUPJR\|UxRTVwMjFOwG0>	NYX2bGg1OTV5MUW0O\|A>
ARP1	MV\GeY5kfGmxbjDBd5NigQ>?	M1i3NlIh\|ryP	NY\2Ung5PiCq		NVT1TWF1UW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NGDvWWoyPDd\|NEiwOi=>
CEM	NHXNclRMcW6jc3WgRZN{[Xl?		MYqxJIg>	MUnEUXNQ	MkfkTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>?	MnvkNVY1OjByNkS=
HCT15	NGnoNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGjvNWo1QCCq		MYfHTVUxRTBwOEKg{txO	MoLuNVY4OjN{Mke=
NCI-H23	NXPRVGdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXW0PEBp		MV\HTVUxRTBwOUKg{txO	NWHp[Y9{OTZ5MkOyNlc>
GM15850	M3zoVmtqdmG\|ZTDBd5NigQ>?	NFH0S5EzNjVizszN	M1:weVk3KGh?	MULEUXNQ	MWTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MVqxOlkzOTN4Nx?=
GM15850	MmiyT4lv[XOnIFHzd4F6	M3v6dVIvPSEQvF2=	MnfQPVYhcA>?	MkLzSG1UVw>?	MWfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MnuyNVY6OjF\|Nke=
GM15850	MoHOT4lv[XOnIFHzd4F6	MWGyMlUh\|ryP	NFTiTI86PiCq	M2\zW2ROW09?	NYjMemNzUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MmLlNVY6OjF\|Nke=
GM15850	NXHHS25JU2mwYYPlJGF{e2G7	NGPWOWEzNjVizszN	NHO1clI6PiCq	M3PCOGROW09?	NWSwWFJLUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NWrub4ZNOTZ7MkGzOlc>
GM15850	NWD5VnRIU2mwYYPlJGF{e2G7	Mnf2Nk42KM7:TR?=	MnvmPVYhcA>?	NWfBPYRSTE2VTx?=	NXzKZo1XUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M1zDWlE3QTJzM{[3
GM15850	M124XWtqdmG\|ZTDBd5NigQ>?	NIXIenkzNjVizszN	MUC5OkBp	NHL4VmRFVVOR	NWfDe\|FLUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M1LGb\|E3QTJzM{[3
U937	M2e2eGZ2dmO2aX;uJGF{e2G7	MYq1JO69VQ>?	NXjYN\|dYOjRiaB?=	NU\RUGQ1TE2VTx?=	NHy1fVFE\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn	NVLUNZliOTdyMES3NVg>
H661	NHvUS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13uWlQ5KGh?		M{[2b2lEPTB;MTFOwG0>	M2HuSVE4OTV5MEC5
U937	M3jC[2Z2dmO2aX;uJGF{e2G7	M1fuXlUh\|ryP	NHfhcmYzPCCq	MVLEUXNQ	M2n4OWlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NVrTUGxzOTd2NEe3OVA>
U937	MXfGeY5kfGmxbjDBd5NigQ>?	Ml3hNUDPxE1?	NVi2RVFmOjRiaB?=	MUjEUXNQ	Mn;2SYZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	NGXXZYgyPzR2N{e1NC=>
RAW264.7	MV;GeY5kfGmxbjDBd5NigQ>?	NUDDSJF7OTBizszN	MoX2NlRp	MWH3ZZRmeg>?	MWXJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR\|UxKG:oIECuO\|Yh\|ryP	MnTNNVc1Pzd3MUi=
RAW264.7	NHjCSGVHfW6ldHnvckBCe3OjeR?=	NHXjNoYyOCEQvF2=	NWLtUJppOjSq	MYD3ZZRmeg>?	M1;hRmlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOS56ODFOwG0>	MoXvNVc1Pzd3MUi=
SC9	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;wdWs1QCCq		M4TrV2lEPTB;MD62NFYh\|ryP	NUHHfGJtOTd3MEeyNVk>
ST14A	MWjGeY5kfGmxbjDBd5NigQ>?	NIfnelA2KG6P	MoTRO\|IhcA>?		M2L4Z2lv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44>	M3XvS\|E4PTZ3OUmz
ST14A	NHL3XZJHfW6ldHnvckBCe3OjeR?=	MmLlOUBvVQ>?	MlLXO\|IhcA>?		NED6S\|BKdmO{ZXHz[UBqdiCHMl[xJI1TVkFiZYjwdoV{e2mxbh?=	M4jVRlE4PTZ3OUmz
PANC1	M2LTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWxJO69VQ>?			MYjJR\|UxRTBwNEWg{txO	Mln0NVc2QDh5NES=
PANC1	NF7YT3RHfW6ldHnvckBCe3OjeR?=	MnnhNUDPxE1?	NWrRT2hLOjRiaB?=		MmTPTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	MVSxO\|U5QDd2NB?=
PANC1	NWmwZ3NOTnWwY4Tpc44hSXO\|YYm=	NIfYWHAyKM7:TR?=	MlfpNlQhcA>?		M2CwRmlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	NHvkb2IyPzV6OEe0OC=>
PT45	NH7uVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\ZZmlEPTB;NDFOwG0>	NIm4NXIyPzV6OEe0OC=>
ACHN	NFTHdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUCyNUBp		NGT0N2JIUTVyPUCuOlUh\|ryP	NIX6c5oyPzZ4Mk[wOi=>
PC3	M3XVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4n6Z\|IyKGh?		NEnsSFlIUTVyPUCuO\|Eh\|ryP	M3izUVE4PjZ{NkC2
A431	NU\xXFRsS3m2b4TvfIlkKEG\|c3H5		NX[5O3FzPzJiaB?=		MmHPTWM2OD12LkKg{txO	NGDYW3MyPzZ7MUe2Ny=>
Cal27	NX7TfWliS3m2b4TvfIlkKEG\|c3H5		Mm\KO\|IhcA>?		MWPJR\|UxRTNwMjFOwG0>	NEjZPGkyPzZ7MUe2Ny=>
CCRF-CEM	M4ixd2N6fG:2b4jpZ{BCe3OjeR?=		Ml\TO\|IhcA>?		NIfyXHdKSzVyPUCuPEDPxE1?	NXvmbWdzOTd4OUG3OlM>
EOL1	MVHDfZRwfG:6aXOgRZN{[Xl?		MlfmO\|IhcA>?		NGTnV\|BKSzVyPUGg{txO	NWnvdYUxOTd4OUG3OlM>
Hec-1-A	NFn5OmJEgXSxdH;4bYMhSXO\|YYm=		M4TzUVczKGh?		MkXOTWM2OD1zIN88US=>	NU\JPVRuOTd4OUG3OlM>
HeLa	MVPLbY5ie2ViQYPzZZk>	MnHYNVAh\|ryP	NGezcW8{OCCvaX6=	NHzST\|ZFVVOR	MlzETY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4xOiEQvF2=	Mn3iNVc3QTF5NkO=
RKOp21	NHOzdnFEgXSxdH;4bYMhSXO\|YYm=		MY[3NkBp		M{LPemlEPTB;MT63OkDPxE1?	MknWNVc3QTF5NkO=
Saos2	M2jVe2N6fG:2b4jpZ{BCe3OjeR?=		NI\rdZA4OiCq		M2r5VWlEPTB;Mj6zJO69VQ>?	NEf5[FUyPzZ7MUe2Ny=>
SK-OV-3	MVXDfZRwfG:6aXOgRZN{[Xl?		M1XkTlczKGh?		MV3JR\|UxRTJwMjFOwG0>	NHH3bVkyPzZ7MUe2Ny=>
U87MG	Mlz0R5l1d3SxeHnjJGF{e2G7		M{HTbFczKGh?		Ml[2TWM2OD1zMTFOwG0>	MXexO\|Y6OTd4Mx?=
NUGC3	M2r6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHjSHo2KM7:TR?=	M1XxRlI1KGh?		MmrWS2k2OD1{Lke5JO69VQ>?	NEXTNIwyPzlyNEi0Ny=>
CCD1059SK	NGO1eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEH6W3BKSzVyPUSzMlUh\|ryP	NIfFUJoyQDJ2N{W1OC=>
HepG2	M1rl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDidFJKSzVyPUCuNFAxPiEQvF2=	M1nh[FE5OjR5NUW0
HT1080	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;Yd5lKSzVyPUCuNFAzPCEQvF2=	MUWxPFI1PzV3NB?=
SKBR3	M3zMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjk[YRUUUN3ME2wMlgh\|ryP	NXy1cYJHOTh{NEe1OVQ>
SNB78	NGrLT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofESWM2OD1zNjFOwG0>	MkSwNVgzPDd3NUS=
SQ20B	NGThNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXqzV\|FSUUN3ME2zJO69VQ>?	MV:xPFI1PzV3NB?=
St4	M2i2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3OwN2VEPTB;NT6yJO69VQ>?	MnT4NVgzPDd3NUS=
MCF7	MV\GeY5kfGmxbjDBd5NigQ>?	Mn3jNVAh\|ryP	NFPtSJk5KGh?	M17hNmROW09?	M2PRSWlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44>	NWjDVlhCOTh{NkmyNlY>
HEK293	NILBSpJMcW6jc3WgRZN{[Xl?		NILjUIcyKGh?	MYnEUXNQ	NGf3fVNKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	NXHHR2huOTh\|MEi1OlM>
HEK293	M4DrZWtqdmG\|ZTDBd5NigQ>?		M33VO\|EhcA>?	M1;uOmROW09?	M{mwbmlvcGmkaYTpc44hd2ZiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNFU4KM7:TR?=	MXWxPFMxQDV4Mx?=
G401	NFO1dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYXCZ\|A{PzJiaB?=	NHHQO4FFVVOR	NFnZZ4hKSzVyPUGg{txO	NHvtVWgyQDN5MEO3Ny=>
HeLa	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4nEelczKGh?	MmfHSG1UVw>?	NGS2V4pKSzVyPUCuOFYh\|ryP	M4\EVFE5OzdyM{ez
Human renal epithelial cell	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIPOO3E4OiCq	NHjVZW1FVVOR	NYTKT\|ltUUN3ME2xOEDPxE1?	MnqzNVg{PzB\|N{O=
U937	MlzUSpVv[3Srb36gRZN{[Xl?	MV:1JO69VQ>?	NVezWG5tOjRiaB?=		NE\RT4JKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:w	MWixPFM5OTJ\|OB?=
U937	M4n3OWZ2dmO2aX;uJGF{e2G7	MlPsOUDPxE1?	NH7jU3kzPCCq		MW\JcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w	MYixPFM5OTJ\|OB?=
U937	NIjkcHFHfW6ldHnvckBCe3OjeR?=	NHfWTI82KM7:TR?=	MYSyOEBp		NHjIZWNKdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44>	Mli0NVg{QDF{M{i=
U937	M4PudWZ2dmO2aX;uJGF{e2G7	NHfDPFQ2KM7:TR?=	Mnu3NlQhcA>?		MYTJcoR2[3Srb36gc4Yh[XCxcITvd4l{	M4XRclE5OzhzMkO4
U937	NEO4elJHfW6ldHnvckBCe3OjeR?=	NHHOXHg2KM7:TR?=	MYCyOEBp		NHi2c4pKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=	M2fKOVE5OzhzMkO4
U937	M1\pWmtqdmG\|ZTDBd5NigQ>?	Mo\6OUDPxE1?	NHHPUmgzPCCq		M3\K[2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{G=	M{TiflE5OzhzMkO4
U937	NEm2fJFMcW6jc3WgRZN{[Xl?	MVS1JO69VQ>?	NWPVcJkyOjRiaB?=		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2	NYDUfHNDOTh\|OEGyN\|g>
HEK-TE	MULGeY5kfGmxbjDBd5NigQ>?	M{K0XFUh\|ryP	NXzUR5pGPmh?	NGfGTHlFVVOR	M{\MT2lv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NUG2WXJ{OTh2M{SxOFQ>
HPDE6c7	MmC5R5l1d3SxeHnjJGF{e2G7	NUe3bmZ5PTBizszN	MWS3NkBp	M171bmROW09?	MWrJR\|UxRTFwMzFOwG0>	NG\ucVYyQDR7NES2Ny=>
Human microvascular epithelial cell	MojOR5l1d3SxeHnjJGF{e2G7	NVzLTG83PTBizszN	M{D5R\|czKGh?	NX3uO3JsTE2VTx?=	NFrXeHNKSzVyPUGuN{DPxE1?	NV\IVYdCOTh2OUS0OlM>
Hup T3	NUjsb3pzS3m2b4TvfIlkKEG\|c3H5	NX;uTJMyPTBizszN	NITtcVc4Omh?	M333dGROW09?	M3nSRWlEPTB;MD64JO69VQ>?	MXyxPFQ6PDR4Mx?=
Mia Paca2	MmHNR5l1d3SxeHnjJGF{e2G7	MnzEOVAh\|ryP	NFnMTno4Omh?	MXHEUXNQ	NW\zU2tRUUN3ME2xMlEh\|ryP	MkTJNVg1QTR2NkO=
Panc 04.03	NFzBbGFEgXSxdH;4bYMhSXO\|YYm=	NXXIZ3FRPTBizszN	NHvpPZQ4Omh?	MmrTSG1UVw>?	M4POTGlEPTB;MT6yJO69VQ>?	NFvkbIwyQDR7NES2Ny=>
SU 86.86	NHe5UnlEgXSxdH;4bYMhSXO\|YYm=	NUDKOVNmPTBizszN	M1rS[\|czcA>?	M{OzfWROW09?	NFy2bppKSzVyPUGuN{DPxE1?	MX[xPFQ6PDR4Mx?=
HEK293	M33YNGtqdmG\|ZTDBd5NigQ>?		NXfRUWpJOyCq		NXvvO3BJUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO\|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1?	MmTENVg2PTh4Nkm=
HeLa	MnvsT4lv[XOnIFHzd4F6		NW\KTndiOiCq		NXHVdG1EUW6qaXLpeIlwdiCxZjDueYNt\WG{IFjERWMhf2m2aDDJR\|UxKG:oIECuNFg{KM7:TR?=	NYDQeZFCOTh3NUi2Olk>
RAW264.7	MXzGeY5kfGmxbjDBd5NigQ>?	M1TjblIh\|ryP	NVfpR5J[Oy53IHi=	NI\QTJFFVVOR	NEX5eJpCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY5n\WO2ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO	NFu3VlQyQDZ2NEm2PS=>
NB4			NF3NfGc1QGh?	M3LaSmROW09?	MnLFTWM2OD1yLk[g{txO	NIfDdZYyQDd{M{O0PS=>
HEK293	MW\GeY5kfGmxbjDBd5NigQ>?	M1TBV\|ExKM7:TR?=	MmjaNlQhcA>?	Mlf1SG1UVw>?	M1q1TWFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[C=>	M2DNXlE6ODJ{Nke1
HCT116	M2THWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrzcIY4Omh?	MnzuSG1UVw>?	MXrJR\|UxRTBwM{Gg{txO	NXLXUGxLOTlyOESyPVQ>
HeLa	M2XPTGtqdmG\|ZTDBd5NigQ>?	MUKyJO69VQ>?	MUezNEBucW5?	Mo\ySG1UVw>?	M1\VOWlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	NGDtfFQyQTB6NEK5OC=>
IGROV1	NXKxfHpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWqzPINOPzJiaB?=	NIf0TGpFVVOR	M{DqWGlEPTB;Mj6yJO69VQ>?	NVPtV\|FiOTlyOESyPVQ>
IGROV1	NYjxc2lJU2mwYYPlJGF{e2G7	MkC2OUDPxE1?	MlLuNlQhcA>?	Mn75SG1UVw>?	M{X5dmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCyNUOgZYNmfHmuYYTpc44>	MmLYNVkxQDR{OUS=
IGROV1	MYXLbY5ie2ViQYPzZZk>	NYTkU4w6OTBizszN	NV\HW5AzPCCq	NInZemxFVVOR	MUTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[U1JPCCjY3X0fYxifGmxbh?=	M4L4flE6ODh2Mkm0
IGROV1	NYrPfVZIU2mwYYPlJGF{e2G7	M1LmeVExKM7:TR?=	MmjzOEBp	M2[0V2ROW09?	M3nQ[GlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>?	MXOxPVA5PDJ7NB?=
T24	MWfLbY5ie2ViQYPzZZk>		M{LhN\|MhcA>?		M3;oSWlv\HWldHnvckBw\iCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>?	M{jRbFE6ODh2M{m1
T24	NEG3ZodMcW6jc3WgRZN{[Xl?		MYizJIg>		M37GU2lv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIFk\XS7bHH0bY9vKHerdHigSWM2OCCxZjCwMlI2KM7:TR?=	M{HkeFE6ODh2M{m1
HeLa	Mm\2T4lv[XOnIFHzd4F6		NYLLUYRnOTVibXnu	MUPEUXNQ	M3TWSmlvcGmkaYTpc44hd2ZiSFTBR\|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>	Ml[3NVkxQTN6OES=
HeLa	NHvGZYpMcW6jc3WgRZN{[Xl?		NHH4bIgyPSCvaX6=	MVvEUXNQ	Mnn0TY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2=	NH\NVI4yQTB7M{i4OC=>
NCI-H69	NXi5VZpvS3m2b4TvfIlkKEG\|c3H5		NWLT[XRMPzJiaB?=	M{HoU2ROW09?	MkDDTWM2OD1{LkC2JO69VQ>?	NHTHXIgyQTB7M{i4OC=>
SKMES1	Mn3lR5l1d3SxeHnjJGF{e2G7		NFvJSIQ4OiCq	NVW0eVN2TE2VTx?=	MVTJR\|UxRTJwNEKg{txO	MXOxPVA6Ozh6NB?=
S2	NXi5Tm0xU2mwYYPlJGF{e2G7	NH;6XHcxNjFvMUCg{txO	NWP0SWREOSCq		NEO2R\|hKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>?	M4i1blE6OzF5NEWw
SHSY5Y	M3PwXGtqdmG\|ZTDBd5NigQ>?	NUXk[nF[OTBizszN	NETRN5Y1QCCq	MUnEUXNQ	M1nz[mlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	NVHMWlJtOTl\|NESxO\|U>
SHSY5Y	NIrOdJJEgXSxdH;4bYMhSXO\|YYm=	MWixNEDPxE1?	MXq0PEBp	NF7OfndFVVOR	M2jZUWlEPTB;MjFOwG0>	Mnn4NVk{PDRzN{W=
DMS114	NYi2NXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\TXVc1QCCq		NXHXZYpoT0l3ME2yMlkh\|ryP	NIXIbVcyQTRzOUKwOS=>
HBC5	NWK0O5pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkjXOFghcA>?		Mm\IS2k2OD1zNzFOwG0>	M2e3PFE6PDF7MkC1
SNB78	NEf2bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVK0PEBp		MYjHTVUxRTF4IN88US=>	MkfxNVk1OTl{MEW=
HeLa	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoryO\|IhcA>?	NVuzbYI6TE2VTx?=	MVXJR\|UxRTBwNE[g{txO	MUSxPVQ1OTh2Nh?=
BHK	MUfLbY5ie2ViQYPzZZk>	NEPVeFg2KM7:TR?=	NUD1UmtoOjRiaB?=	NYe3UnBFTE2VTx?=	NUf1XYIxUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	MVyxPVk3Pjd6OR?=
CFBE41o-	MWTLbY5ie2ViQYPzZZk>	NHLNcoo2KM7:TR?=	NFXrWmw5KGh?	M4PsbmROW09?	NVvGUWZHUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	NHrpbVQyQTl4Nke4PS=>
CFBE41o-	M2nuXmtqdmG\|ZTDBd5NigQ>?	NWCyNlBvPSEQvF2=	NYr6UnhPPCCq	NXrqSnBwTE2VTx?=	M{jhRWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBt\X[nbB?=	MkPoNVk6PjZ5OEm=
CFBE41o-	NFnST5JMcW6jc3WgRZN{[Xl?	MV[xJO69VQ>?	MV6xJIg>	NF3venhFVVOR	NIrKSIVKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs	NGXzRpEyQTl4Nke4PS=>
Primary bronchial epithelial cell	M3jOXmtqdmG\|ZTDBd5NigQ>?	M2DZNFEh\|ryP	NV\t[W9ZOjRiaB?=	NH;XWIxFVVOR	MmXNTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	NFzmV4UyQTl4Nke4PS=>
CFBE41o-	M2nJXWtqdmG\|ZTDBd5NigQ>?	NGDuNpAyKM7:TR?=	MmHCOUBl[Xm\|	NVi2RWxLTE2VTx?=	MoG1TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	M2K0ZlE6QTZ4N{i5
CFBE41o-	MV;LbY5ie2ViQYPzZZk>	M4\DfVEh\|ryP	MWqyOEBp	M4PacWROW09?	NFP3WHZKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	NXX2dpdkOTl7Nk[3PFk>
CFBE41o-	MkeyT4lv[XOnIFHzd4F6	MUi1JO69VQ>?	NXv1dnFnOjRiaB?=	NG\4TGxFVVOR	MnfETY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	Mnq3NVk6PjZ5OEm=
CFBE41o-	MWnLbY5ie2ViQYPzZZk>	M{Lo[\|Uh\|ryP	M{i1W\|I1KGh?	NHLFSHZFVVOR	MWLJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\Wmw	Ml;lNVk6PjZ5OEm=
CFBE41o-	Mk\ZT4lv[XOnIFHzd4F6	NFG0N3k2KM7:TR?=	M{PjblI1KGh?	M1fYZWROW09?	NHOyfINKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHPvdpJm[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIITyZYZncWOtaX7nJJRwKGOnbHygd5Vz\mGlZTDhd{BodHmlb3\vdo0>	M3vWSlE6QTZ4N{i5
Primary bronchial epithelial cell	MXfLbY5ie2ViQYPzZZk>	NXf4Wm5JPSEQvF2=	NYXVRWczOjRiaB?=	MmnQSG1UVw>?	M1vnWGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	MYqxPVk3Pjd6OR?=
Primary bronchial epithelial cell	NIfwbIpMcW6jc3WgRZN{[Xl?	NVvKTZJnOSEQvF2=	MkHZPVYhcA>?	MXvEUXNQ	MVXJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	NHfjfY4yQTl4Nke4PS=>
BxPC3	NUS5eGduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrUO3g4OiCq		MWDJR\|UxRTJwNzFOwG0>	NWjkdmMyOjBzNEO3O\|g>
CAL27	Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2j0eVczKGh?		NX\RTXJnUUN3ME2zMlczKM7:TR?=	NVq3UJZrOjBzNEO3O\|g>
Capan1	NVjq[4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoL1O\|IhcA>?		M1;3TmlEPTB;Nz6zJO69VQ>?	Mof5NlAyPDN5N{i=
HCC827	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\vSFczKGh?		NFjvfJpKSzVyPUGuPEDPxE1?	MoiwNlAyPDN5N{i=
LNCAP	M3;Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGTB[\|I4OiCq		NHrE[HlKSzVyPUCuOVgh\|ryP	NFHGZVQzODF2M{e3PC=>
NCI-H2122	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu3NkBp		MWHJR\|UxRTdwNTFOwG0>	M3nHeVIxOTR\|N{e4
NCI-H358	M13Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY[3NkBp		M2nsSWlEPTB;Mj61JO69VQ>?	NXPRZo9yOjBzNEO3O\|g>
SCC15	NEfXbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M164T\|czKGh?		M3fnU2lEPTB;Mj60PUDPxE1?	NHfhPFczODF2M{e3PC=>
SCC25	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2rxWVczKGh?		NUi1VoJSUUN3ME2xMlk{KM7:TR?=	NEjqZVgzODF2M{e3PC=>
SKHEP1	M123eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;qPWo4OiCq		M{TOfWlEPTB;Mz60OkDPxE1?	NFqwUVIzODF2M{e3PC=>
BJ	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrxNVAxKM7:TR?=	NWnVU2FMPDhiaB?=	MWPEUXNQ	Ml;ZS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	M{S5bFIxOTR\|OESw
MUF	M3HBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXHNVAxKM7:TR?=	MoLJOFghcA>?	NWTveXM6TE2VTx?=	Ml3PS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	M2e5TFIxOTR\|OESw
Caco-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHNUVdXOTByIN88US=>	NI\NO\|I1QGh?	M33QPGROW09?	MWDJR\|UxRThwMTFOwG0>	NEHFW2UzODF2M{i0NC=>
Caco-2	MnHOT4lv[XOnIFHzd4F6	NIT2O4E2KM7:TR?=	MUi0JIg>	M3r6bmROW09?	M4q4ZWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB\|NzFOwG0>	NW\kcYRpOjBzNEO4OFA>
Caco-2	MWDLbY5ie2ViQYPzZZk>	NYT3S4dZOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	M372[\|QhcA>?	NHTjSJZFVVOR	NXLvNoZSTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJJdqfGhiSVO1NEBw\iByLkGxPUDPxE1?	MmnZNlAyPDN6NEC=
Caco-2	NFvQXIxMcW6jc3WgRZN{[Xl?	MXSwMlMyPiCwTTD0c{A{OS54IN88US=>	NHrLWnE1KGh?	NEKxVplFVVOR	M3rJTWV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMzD3bZRpKEmFNUCgc4YhOC5zNEeg{txO	MlW1NlAyPDN6NEC=
Caco-2	NELRSoRMcW6jc3WgRZN{[Xl?	M4Pa[VYvOzJibl2geI8hPjN{IN88US=>	NXXPO49JPCCq	NVS5cmVtTE2VTx?=	NIHUS3JGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Wge4l1cCCLQ{WwJI9nKDF{Lk[g{txO	MmrVNlAyPDN6NEC=
Caco-2	NEfzV2ZMcW6jc3WgRZN{[Xl?	MWq2MlMzKG6PIITvJFY{OiEQvF2=	M3voUVQhcA>?	NUHPVXBSTE2VTx?=	MnfISZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=	NULnPWNDOjBzNEO4OFA>
Caco-2	MYDLbY5ie2ViQYPzZZk>	MXewMlMyPiCwTTD0c{A{OS54IN88US=>	NVX6cnpSPCCq	MUHEUXNQ	NXPKZZNUTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO2	NISxR3EzODF2M{i0NC=>
HepG2	MnnDT4lv[XOnIFHzd4F6	MmLSOUDPxE1?	MlW4Oog>	NWTZd3hiTE2VTx?=	NYjIe\|ZmUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBi[2W2eXzheIlwdg>?	MlPDNlAyPDN6NEC=
HepG2	NW\HPIFQU2mwYYPlJGF{e2G7	NYHnSHBZPSEQvF2=	MVK2bC=>	MkPqSG1UVw>?	MVTJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25?	MUiyNFE1Ozh2MB?=
HepG2	Ml;DT4lv[XOnIFHzd4F6	MnjLOUDPxE1?	Mm[4Oog>	NXvWXYk3TE2VTx?=	NU\xWVNJUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	M{DWblIxOTR\|OESw
HepG2	MX\LbY5ie2ViQYPzZZk>	NVnPVXJwPSEQvF2=	NGjiT2o3cA>?	NEC3b3hFVVOR	MmTmTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgTFMwUDRiaHnzeI9v\SCjY3X0fYxifGmxbh?=	MX[yNFE1Ozh2MB?=
COLO205	MkLZT4lv[XOnIFHzd4F6	M2i2elExKM7:TR?=	NFnPSoIzPCCq	MYLEUXNQ	MWjJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	MmTONlA1PTF\|N{i=
SCC4	NVy3eWp7U2mwYYPlJGF{e2G7	MWOxJO69VQ>?	NUO4PZBoOjSq		M1Xwd2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0eYJ2dGmwIHHj[ZR6dGG2aX;u	MVSyNFQ2OjJ{NR?=
SCC4	MlTVT4lv[XOnIFHzd4F6	NGO0[FgyKM7:TR?=	NXXN[ol[OjSq		NGPsO4RKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	MlPPNlA1PTJ{MkW=
SCC4	MmfzSpVv[3Srb36gRZN{[Xl?	MlLWNUDPxE1?	NWPsUYhIPSCvaX6=		M3X5d2Fod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	MlSzNlA1PTJ{MkW=
NB4	MojCSpVv[3Srb36gRZN{[Xl?	MWG1JO69VQ>?	M37BT\|I1KGh?	MYfEUXNQ	M2TIVmNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHjZ5VufWyjdHnvckBifCCycnWtS\|EheGijc3W=	M4K4TVIxPDlzNESw
NB4	MmHhT4lv[XOnIFHzd4F6	M4nCO\|Uh\|ryP	NYm3SVdQOjRiaB?=	MofCSG1UVw>?	NYXYbJVvUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu	NWDEenRoOjB2OUG0OFA>
NB4	Mm\USpVv[3Srb36gRZN{[Xl?	NX3afVc1PSEQvF2=	NUCwXHc2OjRiaB?=	NHXkTItFVVOR	MoHuTY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;u	MYGyNFQ6OTR2MB?=
NB4	M2XOe2tqdmG\|ZTDBd5NigQ>?	NXfYNYlYPSEQvF2=	M3zVW\|I1KGh?	MonsSG1UVw>?	NX7v[XFrUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMh[WOndInsZZRqd25?	NIjkU40zODR7MUS0NC=>
NUGC3	NWHkW2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXBfYtIUTVyPUKuPVQh\|ryP	NYTvT2F[OjB6NUC5O\|E>
A549	NF\Tc4VHfW6ldHnvckBCe3OjeR?=	Mn;lOUDPxE1?	NIfpOGo{KGh?	MlLMSG1UVw>?	NEnsdlNKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	NW\MTHE5OjB6NUWyNFg>
HUT78	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWTzb3dFPzJiaB?=	MortSG1UVw>?	NV:0WpJCT0l3ME2wMlMh\|ryP	M2XlVFIxQDh2MkC4
U937	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFLVSXM4OiCq	M3;JemROW09?	M2\1dWdKPTB;MD6zPUDPxE1?	NYLDT\|J7OjB6OESyNFg>
A431	M3SwfGN6fG:2b4jpZ{BCe3OjeR?=		NYDnfoY{PzJiaB?=		MkDMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjC0MlIh\|ryP	M1PrUFIyODhyNkK5
A549	MkLRR5l1d3SxeHnjJGF{e2G7		MUe3NkBp		NYrNNGlIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	M{jpNVIyODhyNkK5
CAL27	NYLvOJpsS3m2b4TvfIlkKEG\|c3H5		MnLUO\|IhcA>?		NEfsVXdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN	M4TvdFIyODhyNkK5
HeLa	NYDONWxLS3m2b4TvfIlkKEG\|c3H5		NWPRUIo2PzJiaB?=		NXTTW2d{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjVizszN	NIDKeGozOTB6ME[yPS=>
Sf21	M3mxXmtqdmG\|ZTDBd5NigQ>?		MUGzJIg>		Mlu4TY5pcWKrdHnvckBw\iCIbHHnJJRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOiEQvF2=	MYSyNVA5ODZ{OR?=
SKBR3	NWX1UJh4S3m2b4TvfIlkKEG\|c3H5		M3;GTlczKGh?		MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlYh\|ryP	MVmyNVA5ODZ{OR?=
SKOV3	MYjDfZRwfG:6aXOgRZN{[Xl?		NWKySXR5PzJiaB?=		MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	MXSyNVA5ODZ{OR?=
COR-L23	NVLGeIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH3[IUyOCEQvF2=	NXrUZmR{PzJiaB?=	NEPldHlFVVOR	MUTHTVUxRTFwMTFOwG0>	M1TlNlIyODhyNkS3
DU145	NVfEOJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzWWGwyOCEQvF2=	M4DvXVczKGh?	M2fod2ROW09?	NGj2S5FIUTVyPUGuNFUh\|ryP	MnH1NlExQDB4NEe=
LoVo	M3SxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVixNEDPxE1?	M1uxeVczKGh?	M{TzPGROW09?	NWXsXFc2T0l3ME2xMlch\|ryP	MUSyNVA5ODZ2Nx?=
MCR5-SV2	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTRWYZxOTBizszN	NYi2ZoluPzJiaB?=	M2HCSWROW09?	NYLQU3VjT0l3ME2yMlEh\|ryP	NITRS3UzOTB6ME[0Oy=>
HCT116	MXLLbY5ie2ViQYPzZZk>	NWTjTWZROzBizszN	MlW0N\|AhcA>?	NIrzdWxFVVOR	NWPF[oZCUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	MVGyNVA5ODZ2Nx?=
HCT116	NWjOb\|JnU2mwYYPlJGF{e2G7	NX\4N2dEOzBizszN	NI\lUIs{OCCq	MWTEUXNQ	NGPpc21KdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	Mn;2NlExQDB4NEe=
U937	NV\6VVM2U2mwYYPlJGF{e2G7	NUDHfpZiPSEQvF2=	NGq3cpQzPCCq	MmX5SG1UVw>?	M{jrc2lvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEt7	MmT1NlEzQTJ2OUK=
U937	M1XnTWtqdmG\|ZTDBd5NigQ>?	M3zQZlUh\|ryP	MX[yOEBp	MWLEUXNQ	MmK3TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzF6	MWSyNVI6OjR7Mh?=
U937	M{LpTGtqdmG\|ZTDBd5NigQ>?	MW[1JO69VQ>?	MnnuNlQhcA>?	MmW5SG1UVw>?	NVfVR\|BJUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKHCjbj3hZ4V1gWyjdHXkJIhqe3SxbnWgTFQhdGW4ZXy=	MUmyNVI6OjR7Mh?=
U937	MX;LbY5ie2ViQYPzZZk>	NXz2[HdvPSEQvF2=	M33ybFE2KG2rbh?=	MlO2SG1UVw>?	MWfJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=>	MYSyNVI6OjR7Mh?=
A2780	M2TqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX:wSVNxQTZiaB?=	MW\EUXNQ	NX[1TnNuUUN3ME2xMlYzKM7:TR?=	MkH2NlE3OzR2M{C=
COLO205	M{LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIPDPIQ6PiCq	M2\ObmROW09?	MojTTWM2OD1{LkGyJO69VQ>?	MWqyNVY{PDR\|MB?=
Hep3B	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWLBN49ZPDhiaB?=	M4HIVmROW09?	NHvpNWtIUTVyPUGuNlEh\|ryP	NFvPcoEzOTdzMkG0Oi=>
GM11272	NVnCOopzTnWwY4Tpc44hSXO\|YYm=	NG\tfGcyODBibl2=	M132bFczKGh?	NG[5bZZFVVOR	Ml3UVoVi[3SrdnH0bY9vKG:oIF3lR5AzKG23dHHueEBmgHC{ZYPzbY9vKGG2IEGwJJRwKDFyMDDuUS=>	NGjjTnQzOTh2MEexOi=>
CFBE41o	M1\KV2tqdmG\|ZTDBd5NigQ>?	NXjDWGZmPSEQvF2=		NHPucW5FVVOR	NEfhNGtFd3ewIILl[5Vt[XSrb36gc4YhUESDQ{egZZQhOC5{IITvJFUhfU1?	M4XkVVIyQTh2OUW4
CFBE41o	NVHnWVVDTnWwY4Tpc44hSXO\|YYm=	M2\wWFEh\|ryP	M3LtVVI1KGh?	M2ez[2ROW09?	M3P3dHJme3SxcnH0bY9vKG:oIFPGWHIh\GWudHHGOVA5KG23dHHueEB1emGoZnnjb4lv\yC2bzDj[YxtKHO3cn\hZ4Uh[XNiZ3z5Z49nd3Kvcx?=	Mn;INlE6QDR7NUi=
DU145	NVH5UpZ1U2mwYYPlJGF{e2G7	NFPteYczNjVizszN	NXHTbYY1OjRiaB?=	MkjvSG1UVw>?	M{DNOGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	NIC3UI4zOjJ4MEG2Oi=>
DU145	NF2wO5dMcW6jc3WgRZN{[Xl?	NWDXZnl{PSEQvF2=	MXKyOEBp	M{HSemROW09?	NVjTSndQUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSESgZYNmfHmuYYTpc44>	MYGyNlI3ODF4Nh?=
DU145	M1\iOGtqdmG\|ZTDBd5NigQ>?	Mof4OUDPxE1?	MVSyOEBp	MnHSSG1UVw>?	NFznSWxKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w	MVGyNlI3ODF4Nh?=
786-0	NYGxfJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrqOk4zKM7:TR?=	MU[3NkBp	MljzSG1UVw>?	MnzLS2k2OD1\|LkKg{txO	MoW1NlI1OzV4Nkm=
A498	M{XHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[2MlIh\|ryP	MWC3NkBp	NV7lTmt7TE2VTx?=	NGLFTnJIUTVyPUGuOkDPxE1?	NVXVXY5QOjJ2M{W2Olk>
A549/ATCC	M3S3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPwOk4zKM7:TR?=	MoPMO\|IhcA>?	MXjEUXNQ	M3rLdWdKPTB;MT62JO69VQ>?	MnXsNlI1OzV4Nkm=
ACHN	M13ITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjLOk4zKM7:TR?=	NX60WItkPzJiaB?=	MYHEUXNQ	M4W0fWdKPTB;MT6zJO69VQ>?	NV7iemV6OjJ2M{W2Olk>
BT549	M4S2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3lR\|N{Pi5{IN88US=>	Mn7vO\|IhcA>?	M1\jbWROW09?	NVzaSHdNT0l3ME2xMlMh\|ryP	MnfiNlI1OzV4Nkm=
EKVX	M4PMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnD[VNUPi5{IN88US=>	NHnneog4OiCq	M2WyVmROW09?	NEPTZYxIUTVyPUGuN{DPxE1?	M3Oz[lIzPDN3Nk[5
HCT15	NXz0c2FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWe2MlIh\|ryP	NUXjN3VJPzJiaB?=	M4\zUGROW09?	MXnHTVUxRTJwNTFOwG0>	M32xflIzPDN3Nk[5
HOP92	NIDxcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz5Xpo3NjJizszN	NETGNoI4OiCq	NEPNN\|BFVVOR	MVrHTVUxRTRizszN	MoPaNlI1OzV4Nkm=
IGROV1	M4jUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[2MlIh\|ryP	NX61d3puPzJiaB?=	NVPSV4g6TE2VTx?=	Mn\WS2k2OD1zLkOg{txO	MY[yNlQ{PTZ4OR?=
LOXIMVI	NV23foNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLTWplGPi5{IN88US=>	MknmO\|IhcA>?	NU\wPJBnTE2VTx?=	M33ZSWdKPTB;MTFOwG0>	M2DjV\|IzPDN3Nk[5
M14	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfGOk4zKM7:TR?=	Mn;0O\|IhcA>?	NY\4OJRFTE2VTx?=	MX\HTVUxRTFwMzFOwG0>	MlzRNlI1OzV4Nkm=
MALME-3M	NXK2TWZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYW3cXZpPi5{IN88US=>	MYe3NkBp	M2LoWWROW09?	Mn70S2k2OD1yLkOyJO69VQ>?	NIPWTlczOjR\|NU[2PS=>
MCF10A	NGXsV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1X6N\|YvOiEQvF2=	NV;mbHROPDhiaB?=	NESzXmhFVVOR	NX30SXRKT0l3ME25MlYh\|ryP	MmnsNlI1OzV4Nkm=
MDA-MB-435	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;IVmg3NjJizszN	NXz0PHZFPzJiaB?=	M1XGd2ROW09?	MVrHTVUxRTBwNTFOwG0>	NEfZXXQzOjR\|NU[2PS=>
MDA-MB-468	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HQXVYvOiEQvF2=	MlPkO\|IhcA>?	NVTkV\|kzTE2VTx?=	M2fLRmdKPTB;MD62N{DPxE1?	MXGyNlQ{PTZ4OR?=
MOLT4	NH6xNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELSZWg3NjJizszN	NYPwNZZuPzJiaB?=	MmHGSG1UVw>?	MWfHTVUxRTBwNDFOwG0>	MofYNlI1OzV4Nkm=
NCI-ADR-RES	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\ke2tTPi5{IN88US=>	M3L2ZlczKGh?	NUDnSG01TE2VTx?=	MYHHTVUxRTBwMU[g{txO	M3PQdVIzPDN3Nk[5
NCI-H23	NYr4SYJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXe2MlIh\|ryP	M{\GNVczKGh?	NGfOPZBFVVOR	MWjHTVUxRTFizszN	NYPmXJd2OjJ2M{W2Olk>
NCI-H322M	NVPXfol6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjBNnV{Pi5{IN88US=>	NV7lbGJjPzJiaB?=	NFzM[HVFVVOR	NFLCV5NIUTVyPUCuO\|kh\|ryP	NImxWWIzOjR\|NU[2PS=>
NCI-H460	M1vTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEe2dFI3NjJizszN	MYO3NkBp	MUjEUXNQ	MXLHTVUxRTBwN{mg{txO	NGH1ZVQzOjR\|NU[2PS=>
NCI-H522	NXzJUGJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnTOk4zKM7:TR?=	NH\wSWc4OiCq	M{PORmROW09?	M4[zVmdKPTB;MD61JO69VQ>?	NHnObJEzOjR\|NU[2PS=>
OVCAR3	NXf3SIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnyxOk4zKM7:TR?=	MYm3NkBp	MoX6SG1UVw>?	MUjHTVUxRTFwMzFOwG0>	MlPBNlI1OzV4Nkm=
OVCAR4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHrdHM3NjJizszN	M1nYeVczKGh?	NWmw[3U5TE2VTx?=	NX;Ee5k3T0l3ME20JO69VQ>?	NXzzdGNQOjJ2M{W2Olk>
OVCAR5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUe2MlIh\|ryP	NGPweGg4OiCq	MlzISG1UVw>?	NFjEOXRIUTVyPUCuO\|kh\|ryP	MmXoNlI1OzV4Nkm=
OVCAR8	M1jHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTSOk4zKM7:TR?=	NWnMVZcyPzJiaB?=	M2Th[WROW09?	NWPLSHJ{T0l3ME2wMlUh\|ryP	M3nkUVIzPDN3Nk[5
RXF393	NHHFVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPic5A3NjJizszN	MoSyO\|IhcA>?	MoXaSG1UVw>?	M4\SfWdKPTB;MT6zJO69VQ>?	Mmj3NlI1OzV4Nkm=
SF268	M4TydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorSOk4zKM7:TR?=	M1n5elczKGh?	MXvEUXNQ	NVfKb\|c4T0l3ME2xMlYh\|ryP	NIPYTZUzOjR\|NU[2PS=>
SF295	M2rJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\hblYvOiEQvF2=	NV;BU\|J5PzJiaB?=	MVnEUXNQ	M2rpTGdKPTB;MT62JO69VQ>?	NFnNcZgzOjR\|NU[2PS=>
SF539	M3\1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXjc3Y3NjJizszN	MYW3NkBp	NFTzeoZFVVOR	Mn76S2k2OD1{IN88US=>	M2O4NFIzPDN3Nk[5
SK-MEL-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\3N\|YvOiEQvF2=	NHTndZo4OiCq	NEfJeHpFVVOR	MlPpS2k2OD1zLkOg{txO	MUKyNlQ{PTZ4OR?=
SK-MEL-28	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m5NVYvOiEQvF2=	NH\HVnI4OiCq	MWPEUXNQ	NE\JXI5IUTVyPUGg{txO	MoL4NlI1OzV4Nkm=
SK-MEL-5	M4D4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PYUFYvOiEQvF2=	MWK3NkBp	MkH6SG1UVw>?	Mk\KS2k2OD1yLk[zJO69VQ>?	NW\pZ4JTOjJ2M{W2Olk>
SKOV3	NX7YdGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\OOk4zKM7:TR?=	NFzHU4U4OiCq	NULqfpg6TE2VTx?=	NFjoTWVIUTVyPUGg{txO	M1vNUlIzPDN3Nk[5
SN12C	MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXO2MlIh\|ryP	MnHGO\|IhcA>?	NHLafXhFVVOR	NV60XJdOT0l3ME2yJO69VQ>?	MWKyNlQ{PTZ4OR?=
SNB19	M130[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jTWVYvOiEQvF2=	M{TkOVczKGh?	NGOyTlVFVVOR	NYXzOIloT0l3ME2wMlY{KM7:TR?=	MWWyNlQ{PTZ4OR?=
SNB75	M{Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2L0fFYvOiEQvF2=	MnTVO\|IhcA>?	MnXFSG1UVw>?	MYPHTVUxRTBwN{mg{txO	M1K4dVIzPDN3Nk[5
SR	NGLGZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkKwOk4zKM7:TR?=	NFfXfWI4OiCq	M3jXNGROW09?	M{TiNmdKPTB;MD60JO69VQ>?	MV[yNlQ{PTZ4OR?=
T47D	M3ywRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3OTG5UPi5{IN88US=>	MoXaO\|IhcA>?	MXHEUXNQ	MVHHTVUxRTBwNTFOwG0>	NFe2NnozOjR\|NU[2PS=>
TK10	NEDnU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly3Ok4zKM7:TR?=	MnfUO\|IhcA>?	MmjLSG1UVw>?	NYjRT3d[T0l3ME2wMlY{KM7:TR?=	NF;wcJczOjR\|NU[2PS=>
UACC257	M4TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVe2MlIh\|ryP	NVXzVo0{PzJiaB?=	NX;FNFNUTE2VTx?=	MULHTVUxRTBwNTFOwG0>	MXiyNlQ{PTZ4OR?=
UACC62	NYnuTmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjybXY3NjJizszN	Ml7sO\|IhcA>?	MWHEUXNQ	MXzHTVUxRTBwNDFOwG0>	NYqyR\|NOOjJ2M{W2Olk>
UO31	NVL5OXAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXT6[2FxPi5{IN88US=>	M13keVczKGh?	NVvXd3BPTE2VTx?=	MnXoS2k2OD1yLkWg{txO	M4G5TlIzPDN3Nk[5
Hep3B	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYXKeJJMPDhiaB?=	NEHYVppFVVOR	NFr4VpJIUTVyPUCuOlkh\|ryP	NFzUd4QzOjR\|OUi2Ny=>
BE(2)-C	M{f1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXGyfo14PzJiaB?=	NF3nXFlFVVOR	MUPJR\|cxRTJizszN	NWnpe3c5OjJ7M{KzNVY>
Bel7402	NFT6R\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLjZ\|lWPzJiaB?=	MoroSG1UVw>?	Mke3S2k6OD1zNzFOwG0>	M33zeFI{ODZzM{e2
Bel7404	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnKxO\|IhcA>?	MoPVSG1UVw>?	M37LWmdKQTB;MUig{txO	NIfyWpAzOzB4MUO3Oi=>
BGC823	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzxR41VPzJiaB?=	NELNN5VFVVOR	NF25XVhIUTlyPUeuOUDPxE1?	M4nIXVI{ODZzM{e2
MGC803	M1zZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFPOOlM4OiCq	MWjEUXNQ	NV21fYVnT0l7ME2xNE45KM7:TR?=	M2XmZlI{ODZzM{e2
SGC7901	NUOyfIttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVTHWG9oPzJiaB?=	MYTEUXNQ	NV;zT5ZQT0l7ME25MlQh\|ryP	M3juVVI{ODZzM{e2
SKHEP1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnp[Gk4OiCq	Mm\aSG1UVw>?	NEG5[lhIUTlyPUG3JO69VQ>?	NIjxV4kzOzB4MUO3Oi=>
SMMC7721	NUfldWsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{faTVczKGh?	M3zWRmROW09?	NVnQbW1QT0l7ME2yNEDPxE1?	NWT1eXR4OjNyNkGzO\|Y>
NUGC3	NH;1TFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\NNVAh\|ryP			NHPTbmdIUT1{Lkm0JO69VQ>?	MmP4NlMyPjN\|M{K=
A2780 CisR	Moj5T4lv[XOnIFHzd4F6		NELxZ\|YyQCCq		MUfJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNESg{txO	NYLBPHpEOjN{NUK2NFM>
CAL27 sens	M{XyRWtqdmG\|ZTDBd5NigQ>?		NUXnd4VZOThiaB?=		MYHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{[g{txO	NY\6bXl6OjN{NUK2NFM>
CAL27 CisR	NYCwVYZkU2mwYYPlJGF{e2G7		M3HhO\|E5KGh?		NG[5WYdKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	NHi4[oszOzJ3Mk[wNy=>
KYSE-510 CisR	MnnLT4lv[XOnIFHzd4F6		MkTyNVghcA>?		MkDxTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkW5JO69VQ>?	NHOxVIIzOzJ3Mk[wNy=>
KYSE-510 sens	M2HtfWtqdmG\|ZTDBd5NigQ>?		MVexPEBp		MonHTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO	MYiyN\|I2OjZyMx?=
MDA-MB-231 sens	MlH3T4lv[XOnIFHzd4F6		MoH2NVghcA>?		MVrJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NGfDVFgzOzJ3Mk[wNy=>
MDA-MB-231 CisR	MnzFT4lv[XOnIFHzd4F6		MV[xPEBp		MWnJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	MWmyN\|I2OjZyMx?=
ES2	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF7DO3Y1QCCq	M2LXdWROW09?	NEnW[FBKSzVyPUGyMlch\|ryP	NUmzVHE2OjN2OUO0OFk>
MDA-MB-231	NXnpN2xvU2mwYYPlJGF{e2G7	MXGxNEDPxE1?	MWezNEBucW5?	MUXEUXNQ	NF\ZcZdKdmirYnn0bY9vKG:oIFjERWMz[Q>?	MXGyN\|Q6OzR2OR?=
MDA-MB-231	NXT3bGxlU2mwYYPlJGF{e2G7	MkXSNUDPxE1?	MWWyOEBp	MkP3SG1UVw>?	MkTCTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjY3X0fYxifGmxbjDs[ZZmdHNib3[geJVjfWyrbh?=	MkPxNlM1QTN2NEm=
HS68	MX;DfZRwfG:6aXOgRZN{[Xl?	NHHXUlcyOCEQvF2=	NVj0R2ZGPzJiaB?=	MkDjSG1UVw>?	NFHWb25KSzVyPUSuOkDPxE1?	NGTVdVUzOzV5MEW0Ni=>
MEF	NVnQbWFRS3m2b4TvfIlkKEG\|c3H5	Mln4NVAh\|ryP	M1O4clczKGh?	NVv5W2ltTE2VTx?=	NXi5PZIxUUN3ME20MlQh\|ryP	NVv1S\|h[OjN3N{C1OFI>
BGC823	NUL5[IxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWrEUXNQ	M2XEeGdKPTB;Mz6wPUDPxE1?	MVWyN\|YxOTdyNh?=
High5	NUHkTm5LU2mwYYPlJGF{e2G7		Ml7JNlQhcA>?		Mlv1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1?	MkHkNlM3ODJ3MkO=
High5	M1jwNmtqdmG\|ZTDBd5NigQ>?		MXKyOEBp		MUHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?	NIXIdYczOzZyMkWyNy=>
High5	MVrLbY5ie2ViQYPzZZk>		M1[1[FI1KGh?		MkOxTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6xO{DPxE1?	NU\zemc3OjN4MEK1NlM>
A549	M3jFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MojiSG1UVw>?	NIX3TpJKSzVyPUGuNFc6KM7:TR?=	MmroNlM3PDR{MUC=
HCT116	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLLSG1UVw>?	NWjmXWpuUUN3ME2wMlc2PyEQvF2=	MWmyN\|Y1PDJzMB?=
K562	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlT1SG1UVw>?	NUH5[ol5UUN3ME2wMlY1PSEQvF2=	M{HKZlI{PjR2MkGw
GBC-SD	NVzQOJh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorzOUDPxE1?	MkHWO\|IhcA>?	MXrEUXNQ	MVfJR\|UxRTF2Lkig{txO	M{HBT\|I{PzB5Mk[w
HGC27	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrBXGY2KM7:TR?=	MX[3NkBp	MkToSG1UVw>?	NU\mc2oyUUN3ME21MlQh\|ryP	NXi0VZJSOjN5MEeyOlA>
HL60	M3zTc2tqdmG\|ZTDBd5NigQ>?	MoW5OUDPxE1?	M3PDRVI1KGh?	NH:4PGVFVVOR	MnLyTY5pcWKrdHnvckBw\iCKRFHD	NInw[4ozOzdyN{K2NC=>
Vero	NVvBSlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\USVczKGh?	M1;wNGROW09?	Mn;BTWM2OD1yLkmg{txO	MorPNlM4QDZ2NUK=
NCI60	MoXhR5l1d3SxeHnjJGF{e2G7		MlrROFghcA>?	M370b2ROW09?	M4i4fGdKRTBwNUOg{txO	M4PFNFI1ODF3M{K3
SW620	Mo\SR5l1d3SxeHnjJGF{e2G7		NHfHepI1QCCq	NX7CVpMyTE2VTx?=	NGnp[mxIUT1yLkW0JO69VQ>?	MW[yOFAyPTN{Nx?=
U251	M3XuUWN6fG:2b4jpZ{BCe3OjeR?=		M{LvOFQ5KGh?	MlfRSG1UVw>?	M2L0[2dKRTFwNUOg{txO	NVTQ[YZEOjRyMUWzNlc>
KM12	M{fi[GN6fG:2b4jpZ{BCe3OjeR?=		NFrDWW81QCCq	M3m5bWROW09?	MnftS2k:OS56ODFOwG0>	NIDlOXEzPDBzNUOyOy=>
Hs578T	NH\aeGdEgXSxdH;4bYMhSXO\|YYm=		NF3VfWo1QCCq	M3vHVmROW09?	MVXHTV01Njh\|IN88US=>	NHS1c2kzPDBzNUOyOy=>
MDA-MB-231	M4nm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXEeYxUPDhiaB?=		NYPyVplKUUN3ME2wMlE3KM7:TR?=	M4K1bVI1ODl3MEG2
MCF7	NEft[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFjPW5M1QCCq		NUC3VoVuT0l;MD60OUDPxE1?	NWLJZWQ2OjRzMUm1OVU>
MDA-MB-435	NXHSfnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoSyOFghcA>?		Mn7JS2k:OC56ODFOwG0>	NVrHbphMOjRzMUm1OVU>
AsPC1	NHTVPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYKzNEDPxE1?	MXK0PEBp	M33XV2ROW09?	MWnJR\|UxRTNwNk[g{txO	NV60fYRlOjRzOEWzO\|g>
Jurkat E6.1	MV\LbY5ie2ViQYPzZZk>		NGPneFIzKGh?	Mn7wSG1UVw>?	MVvJcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>?	M2fUOFI1OjZzOE[y
KG1	NXfuNIZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHmOFghcA>?		NFzQWIZKSzVyPUGuNVUh\|ryP	MXKyOFUzPTByMx?=
HEL	M{XCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fLVlQ5KGh?	NGfLVpdFVVOR	MmPvTWM2OD1yLkS5JO69VQ>?	NXX2NZBuOjR4OUSwOVU>
HSC3	M2PTSmN6fG:2b4jpZ{BCe3OjeR?=		MYWxNkBp	MlfCSG1UVw>?	MV3JR\|UxRTBwN{Gg{txO	MojmNlQ4PjZ3NkC=
HT-29	NV7TTmZuS3m2b4TvfIlkKEG\|c3H5		MXqxNkBp	NH7GS4xFVVOR	MYPJR\|UxRTBwN{Kg{txO	NXmxNoN3OjR5Nk[1OlA>
KB	MX;DfZRwfG:6aXOgRZN{[Xl?		M3jvfVEzKGh?	NGn1UXNFVVOR	MWTJR\|UxRTBwN{Wg{txO	NXv2ZmtJOjR5Nk[1OlA>
H460	M1HtZmN6fG:2b4jpZ{BCe3OjeR?=		MlvNNVIhcA>?	MXLEUXNQ	M3i1[GlEPTB;MD64NkDPxE1?	MnHxNlQ4PjZ3NkC=
MONE1	MX3DfZRwfG:6aXOgRZN{[Xl?		NGPnZ\|QyOiCq	MnHDSG1UVw>?	MVXJR\|UxRTFwMUig{txO	NGnST3UzPDd4NkW2NC=>
MKN45	MWHDfZRwfG:6aXOgRZN{[Xl?		M{O1UlEzKGh?	NEnTcGRFVVOR	M1f0TmlEPTB;MT6yOUDPxE1?	NYf3T2p[OjR5Nk[1OlA>
TSGH	NELrTGxEgXSxdH;4bYMhSXO\|YYm=		NYLZfGM6OTJiaB?=	MYPEUXNQ	MWTJR\|UxRTJwMEmg{txO	M1fHV\|I1PzZ4NU[w
HL60	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWfacpdrPzJiaB?=	NFf4OHdFVVOR	MlLLS2k2OD1yLkmzJO69VQ>?	M13xSVI1QTByNUCw
HEK293	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnrlO\|IhcA>?	NGnrR3RFVVOR	M33WbmdKPTB;MUOg{txO	M2Hxb\|I1QTByNUCw
Jurkat	MWrDfZRwfG:6aXOgRZN{[Xl?	MofXNVAxKM7:TR?=	NF\SVYk4OiCq		Ml3iS2k2OD1yLkmg{txO	MmPxNlQ6ODB5NEO=
GM15850	Ml\YT4lv[XOnIFHzd4F6	Mke1Nk42KM7:TR?=	MWi5OkBp	MWHEUXNQ	Mme1[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NE\YNmkyPjl{MUO2Oy=>
GM15850	M4\vNWtqdmG\|ZTDBd5NigQ>?	NIrmeGwzNjVizszN	NX3jUFI3QTZiaB?=	M4DROmROW09?	M4TyWIRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA2KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MVqxOlkzOTN4Nx?=
GM15850	MVHLbY5ie2ViQYPzZZk>	NF3qT2ozNjVizszN	MVO5OkBp	NVX3XGdiTE2VTx?=	Mn\Z[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M1\BTFE3QTJzM{[3
GM15850	NI\INFlMcW6jc3WgRZN{[Xl?	NEG1cZEzNjVizszN	Mk\SPVYhcA>?	MljZSG1UVw>?	Mln0[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M1v5OlE3QTJzM{[3
GM15850	M{LxTmtqdmG\|ZTDBd5NigQ>?	MW[yMlUh\|ryP	NGnWU2I6PiCq	NVfqSHpuTE2VTx?=	NVfUUlho\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NESyeWYyPjl{MUO2Oy=>
GM15850	MlHBT4lv[XOnIFHzd4F6	NXX6eIp3Oi53IN88US=>	Mmq0PVYhcA>?	Mlz4SG1UVw>?	M4HaTYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NEH4TFQyPjl{MUO2Oy=>
GM15850	MWrGeY5kfGmxbjDBd5NigQ>?	Mn3yOUDPxE1?	NHLlTHAyOiCq	M1:4d2ROW09?	NIrTe3Np[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	Mkj1NVY6OjF\|Nke=
U937	NGCx[nFMcW6jc3WgRZN{[Xl?	Mo\0OUDPxE1?	NUPHbGo3OjRiaB?=	MoKzSG1UVw>?	NXrsOHUxcGG\|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	NVLqRm9wOTd2NEe3OVA>
U937	NFjOPZZMcW6jc3WgRZN{[Xl?	MknUNUDPxE1?	MU[yOEBp	MUHEUXNQ	MVHoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	MV[xO\|Q1Pzd3MB?=
PANC1	NILLTXJHfW6ldHnvckBCe3OjeR?=	MnjQNUDPxE1?	M3u2WFI1KGh?		NUjP[WNt\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	M2OyeVE4PTh6N{S0
PANC1	M4TBb2Z2dmO2aX;uJGF{e2G7	M{KyOFEh\|ryP	M3zXOFQ5KCCq		Mmr5[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	NEHEblAyPzV6OEe0OC=>
Caco-2	Mn\tSpVv[3Srb36gRZN{[Xl?	NYe1bGg4PSEQvF2=	MkjONlQhcA>?	MlTISG1UVw>?	MX7kc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	MYCyNFE1Ozh2MB?=
SCC4	MV;GeY5kfGmxbjDBd5NigQ>?	MmHMNUDPxE1?	M2fSNlExKG2rbh?=	MXzEUXNQ	MVXoZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	NH3rZmwzODR3MkKyOS=>
A549	MUTGeY5kfGmxbjDBd5NigQ>?	MYK1JO69VQ>?	M{\jSlMhcA>?	M3n2VGROW09?	NGPU[Ydld2W\|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	NIOwclIzODh3NUKwPC=>
HCT116	Mn\yT4lv[XOnIFHzd4F6	MVOwMlMh\|ryP	NWO2XFMyOzBiaB?=	M2X4d2ROW09?	M3fxOYRw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	NIjIXoYzOTB6ME[0Oy=>
HepG2	MkLYSpVv[3Srb36gRZN{[Xl?	NHGycpUyOCEQvF2=	MXSyOEBp	NELaVGlFVVOR	MnXP[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	NUjiclI1OjF3NEi1PFI>
GM11272	MXLGeY5kfGmxbjDBd5NigQ>?	MXywMlEh\|ryP	Mm\1O\|IhcA>?	NUK3NJJITE2VTx?=	MlP4[I9meyCwb4SgdoVi[3SrdnH0[UBO\UOyMjDteZRidnRiZYjwdoV{e2mxbh?=	MXyyNVg1ODdzNh?=
MDA-MB-231	MYnLbY5ie2ViQYPzZZk>	NYfEfYQ{OTBizszN	NVfRVIdYPSCvaX6=	NXe1W\|VjTE2VTx?=	MX;kc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>?	NEf2dlEzOzR7M{S0PS=>
MDA-MB-231	NXLYclVRU2mwYYPlJGF{e2G7	NXHJPZlvOSEQvF2=	MXKyOEBp	Mn:0SG1UVw>?	NXnFTZdv\G:nczDuc5QhcW6qaXLpeEBJTEGFNjDhd5Nme3OnZDDhd{Bi[2W2eXzheIlwdiCuZY\lcJMhd2ZidIXieYxqdg>?	MYCyN\|Q6OzR2OR?=
K562	M4f2XGtqdmG\|ZTDBd5NigQ>?				NFuzVXJld2W\|IH7veEBqdmirYnn0JGhFSUN?	NHixS4QzOzV7MUGxNS=>
Jurkat	MoniR5l1d3SxeHnjJGF{e2G7	NFPVfZMzOCEQvF2=	M1vsd\|czKGh?	M3THfGROW09?	MXfuc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36=	MX:yOFMxPDN2OB?=
HCT116	MX7BdI9xfG:\|aYOgRZN{[Xl?	MX2zJO69VQ>?	MYWyOEBp	M1fjT2ROW09?	MkXx[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCyNUOgdJJwfGWrbjDs[ZZmdA>?	NWjHO3FSOjR5Nk[1OlA>
KASUMI-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLmTHhKSzVyPUm5MlE4KG6P	MV3TRW5ITVJ?
KARPAS-45	NXPYXIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnuxTWM2OD1zN{OuPFkhdk1?	M1\lbHNCVkeHUh?=
BHT-101	NVHqSlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX4XnRKSzVyPUK0OE4yQCCwTR?=	MorvV2FPT0WU
H9	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTJ3NT6wOEBvVQ>?	NELBWo1USU6JRWK=
PA-1	M3zUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXjdHNKSzVyPUK4Ok4zPiCwTR?=	MlzYV2FPT0WU
NEC8	M3uyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmewTWM2OD1{OEmuN\|ghdk1?	M2PROXNCVkeHUh?=
MHH-PREB-1	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLxPJpqUUN3ME2yPVQvPTNibl2=	Mn\YV2FPT0WU
NB7	NIXNZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPrdnVCUUN3ME2zOFUvPzRibl2=	MYjTRW5ITVJ?
A3-KAW	NWnDUI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfDOVN2UUN3ME20NFAvPTlibl2=	NEDOZ45USU6JRWK=
NB69	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXvVXh5UUN3ME20NVEvPzFibl2=	M4rzXXNCVkeHUh?=
EoL-1-cell	MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTR3NEK1JI5O	NWHSRm1uW0GQR1XS
CHP-212	M4XvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfSclZKSzVyPUS1O{42OyCwTR?=	NXnicm5XW0GQR1XS
C2BBe1	M1XtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjmRphSUUN3ME20O\|IvOTlibl2=	Mn3VV2FPT0WU
697	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\6TWM2OD12N{OuOFEhdk1?	NVnKUFlYW0GQR1XS
BCPAP	NVSzfHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fUNWlEPTB;NUCxMlQzKG6P	Mn3EV2FPT0WU
L-363	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrNSWdzUUN3ME21NFMvOSCwTR?=	NXvnPWhUW0GQR1XS
ES8	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrlU3lKSzVyPUWyN{42OyCwTR?=	M{DhUnNCVkeHUh?=
BE-13	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTV{Nj65OkBvVQ>?	NH[zdnRUSU6JRWK=
CTB-1	MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTV\|Nz65NkBvVQ>?	NUTQbI5CW0GQR1XS
HD-MY-Z	NXTCbHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTCTWM2OD13M{iuNVMhdk1?	NFnpRYxUSU6JRWK=
NKM-1	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jX[2lEPTB;NUS0MlI4KG6P	Moe0V2FPT0WU
NCI-H720	NVPXXXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHq3fVVKSzVyPUW2NE4yQCCwTR?=	M4TNeXNCVkeHUh?=
KY821	Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjoe4o4UUN3ME21OlMvOjVibl2=	MUXTRW5ITVJ?
OVCAR-5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\PT4RKSzVyPUW3Ok4yOSCwTR?=	M2\UbHNCVkeHUh?=
CTV-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTV6MT61OkBvVQ>?	M2r3eXNCVkeHUh?=
P12-ICHIKAWA	NFnUeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfaTWM2OD13OU[uOVEhdk1?	MXPTRW5ITVJ?
DB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTV7OD61O{BvVQ>?	M33EWHNCVkeHUh?=
CHL-1	M4nsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP1WZVKSzVyPU[0Nk4xQCCwTR?=	MlTuV2FPT0WU
A4-Fuk	M{\zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\yOmlEPTB;NkS0MlkyKG6P	MlPYV2FPT0WU
MV-4-11	M{S3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3nPG9kUUN3ME22OVkvOSCwTR?=	NITURlVUSU6JRWK=
RPMI-8226	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\xRYRKSzVyPU[3PE4yQCCwTR?=	NHLTS5pUSU6JRWK=
NB14	NX;0ZohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDab45KSzVyPU[5Ok46PSCwTR?=	MUjTRW5ITVJ?
DOHH-2	NWLtV5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy4TIhKSzVyPUewOk43QCCwTR?=	Mnu4V2FPT0WU
D-423MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXqW\|ZKUUN3ME23NFYvQDlibl2=	M1i0R3NCVkeHUh?=
D-283MED	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHTTWM2OD15MUSuNVQhdk1?	NUDVdIxnW0GQR1XS
ES1	NITDeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnq4TWM2OD15MkSuOEBvVQ>?	NU\wN3VxW0GQR1XS
GOTO	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXtWZZKSzVyPUeyPU4yOiCwTR?=	MV;TRW5ITVJ?
NCI-H209	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPG[3hQUUN3ME23NlkvQSCwTR?=	NGTRcmNUSU6JRWK=
MOLT-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETocIRKSzVyPUezPE46QCCwTR?=	M{X4S3NCVkeHUh?=
ATN-1	NX3ySJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvkUGJKSzVyPUe0NE4zQCCwTR?=	M3zkfnNCVkeHUh?=
DU-4475	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknvTWM2OD15NUGuPVEhdk1?	M2nTVnNCVkeHUh?=
NB10	M3vMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTd3MT65NkBvVQ>?	NHTHOWxUSU6JRWK=
KG-1	NU\KW4F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnJTWM2OD15N{WuOFUhdk1?	NVrBN\|FpW0GQR1XS
MOLT-4	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP2TWM2OD15OEeuOFYhdk1?	NYj3WHpXW0GQR1XS
TE-1	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TlRWlEPTB;N{mxMlEhdk1?	NFjqPWdUSU6JRWK=
SBC-1	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGP3PG9KSzVyPUe5N{45PCCwTR?=	M{jDcXNCVkeHUh?=
HEL	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[0TWM2OD16ME[uNFghdk1?	MUfTRW5ITVJ?
SK-MEL-2	M{Tv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zWfGlEPTB;OEC5MlQ1KG6P	MW\TRW5ITVJ?
KU812	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\KS3VZUUN3ME24NVMvOSCwTR?=	NGnUeWhUSU6JRWK=
RPMI-8866	NWP4c2Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRThzMz62O{BvVQ>?	MknRV2FPT0WU
ALL-PO	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TsNmlEPTB;OEG0MlY3KG6P	MmW5V2FPT0WU
LU-139	NHfuOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGG2NJhKSzVyPUiyNk45PiCwTR?=	MX7TRW5ITVJ?
RS4-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXGfnZKSzVyPUizNk41PSCwTR?=	NIP4WWNUSU6JRWK=
EW-18	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTh\|Mj65OkBvVQ>?	MVjTRW5ITVJ?
P30-OHK	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\xSGlEPTB;OEO1Mlchdk1?	NV\oR4JYW0GQR1XS
D-566MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT6ZY5jUUN3ME24N\|gvPjJibl2=	MkDqV2FPT0WU
HSC-4	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYX5e4dwUUN3ME24OFYvPTFibl2=	NFS4eoxUSU6JRWK=
QIMR-WIL	M{jCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33rRmlEPTB;OE[yMlA{KG6P	MnL6V2FPT0WU
SW954	M3n2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEC3T2RKSzVyPUi2N{4yPiCwTR?=	M2\GXnNCVkeHUh?=
HGC-27	NGnz[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTh5Mj6zOEBvVQ>?	MoixV2FPT0WU
HH	NHLFPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTh7ND6xNkBvVQ>?	M17jTnNCVkeHUh?=
KE-37	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTh7ND62NkBvVQ>?	Ml7EV2FPT0WU
SK-N-DZ	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnZdG9KSzVyPUmwNE41OyCwTR?=	NH;2RXlUSU6JRWK=
J-RT3-T3-5	NYDnWYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LDOGlEPTB;OUGwMlQ6KG6P	NXG2OJBZW0GQR1XS
A427	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfkbnhKSzVyPUmyNE45PCCwTR?=	NV7I[VE3W0GQR1XS
ECC10	NF;5PGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzhTWM2OD17NEWuPFchdk1?	MX\TRW5ITVJ?
EW-1	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrGTWM2OD17NEeuNlYhdk1?	NX7DdFh3W0GQR1XS
MIA-PaCa-2	M4fQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHUR3pJUUN3ME25OFkvOTJibl2=	MVfTRW5ITVJ?
HCC2218	NF3EfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTl3OD60PEBvVQ>?	Mo\CV2FPT0WU
HAL-01	M1vjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH[0e3ZKSzVyPUm2PE4xPCCwTR?=	M3LGXHNCVkeHUh?=
RD	M4\6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PyVWlEPTB;OUe0MlQ2KG6P	NX\xSJVCW0GQR1XS
SK-N-AS	M2Wyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHGbGxKSzVyPUm4PE4yKG6P	M{fpTHNCVkeHUh?=
ML-2	M2\l[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\GfJZKSzVyPUGuNFA1ODdizszN	NUnLTYc2W0GQR1XS
MEL-HO	NXjGRYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXxTWM2OD1zLkCwOVgzKM7:TR?=	NWLpN2JvW0GQR1XS
MS-1	NWT5cFMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTFwMEC2NVch\|ryP	NFeyW4dUSU6JRWK=
NCI-SNU-1	M1y4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFwMEKzN\|Eh\|ryP	MYfTRW5ITVJ?
8505C	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfNSpdKSzVyPUGuNFI{OzFizszN	MUjTRW5ITVJ?
MN-60	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTFwMEK2PEDPxE1?	NXn1S3ZMW0GQR1XS
SAS	M{P1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfkS2lKSzVyPUGuNFQxQDFizszN	MY\TRW5ITVJ?
EFM-19	M1fQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4r1eGlEPTB;MT6wOFg4QSEQvF2=	NET6fXlUSU6JRWK=
Ca9-22	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3aUnB4UUN3ME2xMlA2OTB5IN88US=>	NHL4UYxUSU6JRWK=
NBsusSR	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnROZZEUUN3ME2xMlA2OTZ4IN88US=>	NYPU[\|QxW0GQR1XS
NB13	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnFTWM2OD1zLkC1OVAyKM7:TR?=	NET3XVdUSU6JRWK=
SF295	NI\WfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrxVo5KSzVyPUGuNFY3OjRizszN	MnvJV2FPT0WU
U-2-OS	MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2facmlEPTB;MT6wO\|kyOSEQvF2=	MXLTRW5ITVJ?
NCI-H526	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLhTWM2OD1zLkC4NlkyKM7:TR?=	MliwV2FPT0WU
KMOE-2	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX64XldiUUN3ME2xMlA6PDJ{IN88US=>	M33CSHNCVkeHUh?=
RCM-1	NUPqS\|NCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXPeZhKSzVyPUGuNVIyODJizszN	M2nPb3NCVkeHUh?=
MC116	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEf4cppKSzVyPUGuNVM3OjFizszN	M4T1PXNCVkeHUh?=
NCI-H1092	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrqTWM2OD1zLkG1OFA3KM7:TR?=	NG\PXWhUSU6JRWK=
EW-3	NFPEZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nOeWlEPTB;MT6xO\|IyOiEQvF2=	MVTTRW5ITVJ?
HCT-116	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwMUe3OUDPxE1?	NX;pfJpTW0GQR1XS
MC-IXC	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\QTJd6UUN3ME2xMlE4QDhzIN88US=>	Mn7sV2FPT0WU
LB1047-RCC	NH3rdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXPTWM2OD1zLkG4N\|EzKM7:TR?=	NIfBfZVUSU6JRWK=
VM-CUB-1	NX\qRXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDGbYVWUUN3ME2xMlE6OTB6IN88US=>	MkTqV2FPT0WU
NB5	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XTW2lEPTB;MT6xPVg2PiEQvF2=	MULTRW5ITVJ?
SKG-IIIa	NFjv[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PwUmlEPTB;MT6yN\|Q3PCEQvF2=	M{XDeHNCVkeHUh?=
HO-1-N-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HNZWlEPTB;MT6yN\|g{PSEQvF2=	MoruV2FPT0WU
EFO-27	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rCeWlEPTB;MT6yOVA1OyEQvF2=	NI\m[5JUSU6JRWK=
MHH-NB-11	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HGUmlEPTB;MT6yPFMzQSEQvF2=	NX;xU\|ZyW0GQR1XS
SW620	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXBSopKSzVyPUGuNlkxOThizszN	M1PWUnNCVkeHUh?=
MOLT-16	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ryVmlEPTB;MT6yPVc6PyEQvF2=	MWPTRW5ITVJ?
NTERA-S-cl-D1	M3\6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFwM{G3OlEh\|ryP	NX;YdZg1W0GQR1XS
VA-ES-BJ	M4LXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYL3WFY2UUN3ME2xMlMzPDd5IN88US=>	NXzxN242W0GQR1XS
HCC1419	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXsephKSzVyPUGuN\|QxOjdizszN	MlfmV2FPT0WU
NCI-H69	NVTZPXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXSyPYJ1UUN3ME2xMlM1OTF{IN88US=>	M17Oc3NCVkeHUh?=
DEL	NIq4fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFwM{WxOlIh\|ryP	MmLuV2FPT0WU
LXF-289	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFwM{WyOEDPxE1?	NX2yenZSW0GQR1XS
EW-11	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFwM{[wNlYh\|ryP	NEWxUJhUSU6JRWK=
KP-4	NX;BWpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojiTWM2OD1zLkO3NFg2KM7:TR?=	MWHTRW5ITVJ?
NOS-1	NFfEW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfJflhKSzVyPUGuOFEyQTRizszN	M3rnS3NCVkeHUh?=
SK-NEP-1	NEexd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnqXJdKSzVyPUGuOFE3QTNizszN	NHfHdmVUSU6JRWK=
LAMA-84	M13NV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYGyVpRlUUN3ME2xMlQ{QTR3IN88US=>	MVnTRW5ITVJ?
ES5	NXfIXItMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfhVIFbUUN3ME2xMlQ1OyEQvF2=	NGnob5ZUSU6JRWK=
HuO9	M2jEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NES0RoZKSzVyPUGuOFU{PjJizszN	MontV2FPT0WU
COLO-684	M{PPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFwNE[xNVgh\|ryP	MXLTRW5ITVJ?
EW-24	NIXR[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSwTWM2OD1zLkS2OVMyKM7:TR?=	M2rnN3NCVkeHUh?=
BV-173	NXvJZ5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwNEeyPVEh\|ryP	NHGwOGpUSU6JRWK=
NCI-H1770	NVLZOWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml:5TWM2OD1zLkS4OVM3KM7:TR?=	M2jwSnNCVkeHUh?=
HuP-T4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnqTWM2OD1zLkS5N{DPxE1?	MYrTRW5ITVJ?
TYK-nu	M3TOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLGfGlvUUN3ME2xMlQ6QDVzIN88US=>	NXr2PI9KW0GQR1XS
YH-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXpTWM2OD1zLkS5PFk1KM7:TR?=	NHGxToZUSU6JRWK=
H4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrBVW9YUUN3ME2xMlUxQTF{IN88US=>	NIm3N2lUSU6JRWK=
OVCAR-8	M2fiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGq2VmVKSzVyPUGuOVQ1PzdizszN	NYrpcYR6W0GQR1XS
NCI-H23	NVT2XY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofYTWM2OD1zLkW0OlQ2KM7:TR?=	MkLqV2FPT0WU
ES7	NV:5XoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17GXGlEPTB;MT61OFc4OyEQvF2=	Ml;rV2FPT0WU
COR-L88	M1v2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjPblVxUUN3ME2xMlU3PDJ2IN88US=>	M2X4XnNCVkeHUh?=
TI-73	NIDUSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjEXpR2UUN3ME2xMlU6ODZizszN	M{nWd3NCVkeHUh?=
RT-112	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TETWlEPTB;MT61PVI5PCEQvF2=	MmnJV2FPT0WU
HuO-3N1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLyTWM2OD1zLkW5N\|g2KM7:TR?=	NWPSVYhzW0GQR1XS
HC-1	NFPVXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnycnViUUN3ME2xMlU6QDZ4IN88US=>	NIDsbXZUSU6JRWK=
HT55	M36wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXIZ5l7UUN3ME2xMlY2OTNzIN88US=>	NELYXlVUSU6JRWK=
IA-LM	NFr2XmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\hfYhKSzVyPUGuOlkzPzhizszN	NITJU3BUSU6JRWK=
EM-2	NIHqboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfTTWM2OD1zLkewNFE1KM7:TR?=	M3:1R3NCVkeHUh?=
MHH-ES-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDoVJRyUUN3ME2xMlcxPDN3IN88US=>	NX7v[WFOW0GQR1XS
CAL-27	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PrZWlEPTB;MT63NFYzOSEQvF2=	M4LsdnNCVkeHUh?=
COLO-800	NFyxUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\Be4ltUUN3ME2xMlcyOTd7IN88US=>	MlzDV2FPT0WU
HCE-T	M1npW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zsfmlEPTB;MT63NVUh\|ryP	NIr3cJpUSU6JRWK=
CAMA-1	NEWwRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTFwN{G5O\|Eh\|ryP	NF3GPYZUSU6JRWK=
LOXIMVI	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\ESGlEPTB;MT63NlEyKM7:TR?=	MlzhV2FPT0WU
NH-12	M1f5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HiW2lEPTB;MT63NlY6OSEQvF2=	MU\TRW5ITVJ?
TCCSUP	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnudnVTUUN3ME2xMlczQDJ7IN88US=>	MUDTRW5ITVJ?
MDA-MB-361	M3LrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnWdpBOUUN3ME2xMlc{OTV5IN88US=>	NYPJZopIW0GQR1XS
EW-16	NW[4XmZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjzTWM2OD1zLke0NVA4KM7:TR?=	MV7TRW5ITVJ?
SNU-423	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTFwN{W4Nlch\|ryP	MUjTRW5ITVJ?
Daoy	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\3OmVMUUN3ME2xMlc3OzF7IN88US=>	Mn;DV2FPT0WU
ES4	NVvlSGRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFwN{i3OFEh\|ryP	Mo\3V2FPT0WU
PFSK-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vXSmlEPTB;MT64NFM4KM7:TR?=	Mof2V2FPT0WU
ES3	NUCzeJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknFTWM2OD1zLkiyOlgyKM7:TR?=	NWTtOGVJW0GQR1XS
ONS-76	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFwOEK4PVch\|ryP	M4f1OHNCVkeHUh?=
JVM-3	M1fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwOEW0OVEh\|ryP	MUHTRW5ITVJ?
OS-RC-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fEcGlEPTB;MT64O\|E2OSEQvF2=	NYTXT5JGW0GQR1XS
COLO-320-HSR	NULHN4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwOEixPVch\|ryP	MV7TRW5ITVJ?
HN	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zsTGlEPTB;MT64PFczPSEQvF2=	M2jh[XNCVkeHUh?=
HT	NVfifGR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HIeWlEPTB;MT64PFk1PyEQvF2=	Mo\1V2FPT0WU
LoVo	NEXaR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFwOEm4NUDPxE1?	M4HIV3NCVkeHUh?=
CGTH-W-1	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrENlR1UUN3ME2xMlg6QTR4IN88US=>	M2G3cXNCVkeHUh?=
NB6	M{S3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XG[mlEPTB;MT65NVI6QCEQvF2=	MkfiV2FPT0WU
EW-22	M17SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjYTWM2OD1zLkmyPFg4KM7:TR?=	MYPTRW5ITVJ?
ES6	NFjwOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fISmlEPTB;MT65N\|Y{OSEQvF2=	MknxV2FPT0WU
SCC-15	NEfafXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M333XWlEPTB;MT65N\|gyQSEQvF2=	NUXnTGFJW0GQR1XS
HL-60	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwOUO5NFIh\|ryP	NYHC[mJvW0GQR1XS
human HOP-92	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPXZnRKSzVyPUGuPVQxPjVizszN	Mm\sV2FPT0WU
SW626	NEe5V5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7qTWM2OD1zLkm0PFk6KM7:TR?=	MlrjV2FPT0WU
HEC-1	NYr6[Gt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XFTmlEPTB;MT65OVM3KM7:TR?=	M3\Z[HNCVkeHUh?=
LB2241-RCC	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnu5TWM2OD1zLkm4NlMyKM7:TR?=	MXzTRW5ITVJ?
Ramos-2G6-4C10	NEftOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrMTWM2OD1zLkm5OFk{KM7:TR?=	NULKOY5uW0GQR1XS
A101D	M4qxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGqxflNKSzVyPUKuNlA{ODNizszN	MYrTRW5ITVJ?
NCI-H446	M3\sTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwMES1PVkh\|ryP	NYSzRnlRW0GQR1XS
SBC-5	NFLOcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X5bGlEPTB;Mj6wOlE1PyEQvF2=	MlOxV2FPT0WU
HOS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfMTGx1UUN3ME2yMlA4PjV\|IN88US=>	NYLpNXVuW0GQR1XS
K5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnlN4JKSzVyPUKuNFc5OTFizszN	Ml7mV2FPT0WU
HLE	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDFZotlUUN3ME2yMlA5PTJ7IN88US=>	NVjN[npsW0GQR1XS
HSC-2	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1v2XWlEPTB;Mj6xNlg6QCEQvF2=	MnOxV2FPT0WU
LCLC-97TM1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJwMUS1PFMh\|ryP	MlzwV2FPT0WU
DMS-273	NGq0UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXiRZVnUUN3ME2yMlE1QDN5IN88US=>	NXuxRZNyW0GQR1XS
TE-8	NIjFbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDLTWM2OD1{LkG1O\|Y2KM7:TR?=	NVzR[JFlW0GQR1XS
DSH1	NGT2XJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;oTWM2OD1{LkG2N\|k5KM7:TR?=	NIe2N2hUSU6JRWK=
CAL-51	NYPZeGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLSUmxKSzVyPUKuNVY3QTlizszN	NVXnPVA1W0GQR1XS
IST-SL1	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PGdGlEPTB;Mj6xOlg1PCEQvF2=	MWHTRW5ITVJ?
GCT	NWfUfG9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJwMUe3O{DPxE1?	MlTRV2FPT0WU
SW948	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkWyTWM2OD1{LkG4OFU3KM7:TR?=	MY\TRW5ITVJ?
NOMO-1	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJwMUmzNVch\|ryP	NG\yOIJUSU6JRWK=
C8166	M4Gycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJwMkGzN\|Qh\|ryP	MnzCV2FPT0WU
OC-314	M3LsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknpTWM2OD1{LkKzNlU6KM7:TR?=	NYS4OZZRW0GQR1XS
CAL-39	M4Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzVTWM2OD1{LkKzOlI3KM7:TR?=	NGHVbYJUSU6JRWK=
MDA-MB-453	NF;NbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XiU2lEPTB;Mj6yOFI4PSEQvF2=	M4jNSHNCVkeHUh?=
A673	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjxTWM2OD1{LkK1PFYzKM7:TR?=	MXPTRW5ITVJ?
HTC-C3	NY\OVo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHuTWM2OD1{LkK2PFUh\|ryP	NWq3eIRDW0GQR1XS
NCI-H1666	NX3FRVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjj[WFKSzVyPUKuNlgyOTFizszN	NEDreVBUSU6JRWK=
PSN1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDITWM2OD1{LkK4PVE{KM7:TR?=	NIriZXlUSU6JRWK=
GI-1	M3fiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJwM{C1OFMh\|ryP	MUTTRW5ITVJ?
HuH-7	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvwflVGUUN3ME2yMlMxPjN5IN88US=>	MXfTRW5ITVJ?
JAR	M1i4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXsVJlNUUN3ME2yMlMyQTh5IN88US=>	MX\TRW5ITVJ?
5637	M3vYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYiyNZl[UUN3ME2yMlMzOTJ7IN88US=>	M2LzbnNCVkeHUh?=
GB-1	M2XrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTOTWM2OD1{LkOyN\|M2KM7:TR?=	M1XjNHNCVkeHUh?=
KP-N-YS	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmP6TWM2OD1{LkOyOlE2KM7:TR?=	MXHTRW5ITVJ?
OAW-42	NX[1SYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwM{O0NVYh\|ryP	M2XjWXNCVkeHUh?=
8-MG-BA	NGLsPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJwM{O5NFYh\|ryP	NV\OXXYzW0GQR1XS
RH-18	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf0SmZ2UUN3ME2yMlM2ODJ{IN88US=>	NFKxSmdUSU6JRWK=
NCI-H1155	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO4Z2RrUUN3ME2yMlM3PzJ3IN88US=>	NUjZOnI5W0GQR1XS
NB17	NVXXVXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJwM{iyOFMh\|ryP	MVTTRW5ITVJ?
NCI-H1437	NV;tWJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7aTWM2OD1{LkSxPFc{KM7:TR?=	Ml7oV2FPT0WU
SN12C	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV60b2IzUUN3ME2yMlQ{OjF2IN88US=>	M2nOUHNCVkeHUh?=
HSC-3	NID3eo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2La[2lEPTB;Mj60OFUxQSEQvF2=	NGfJT5NUSU6JRWK=
GAMG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1X4dGlEPTB;Mj60OFU3OSEQvF2=	NW\1dmJrW0GQR1XS
HT-1080	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfiTWM2OD1{LkS0PFY1KM7:TR?=	M3LqUHNCVkeHUh?=
A549	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTJwNES4PVMh\|ryP	NWD5UHRHW0GQR1XS
KNS-62	Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTJwNEWwOlEh\|ryP	M3S0bnNCVkeHUh?=
YKG-1	NX7hT5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED4[HZKSzVyPUKuOFU1OzdizszN	MXzTRW5ITVJ?
LU-134-A	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PHS2lEPTB;Mj60O\|AxQCEQvF2=	Ml3GV2FPT0WU
FADU	M1XrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nTO2lEPTB;Mj60O\|E3OiEQvF2=	MoH6V2FPT0WU
TGBC11TKB	M4\UU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnDTWM2OD1{LkS3NVc4KM7:TR?=	M{\U[3NCVkeHUh?=
HT-3	NVnCfmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXDUldHUUN3ME2yMlQ6PTN3IN88US=>	M{XFZ3NCVkeHUh?=
NCI-H2170	M3WwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fyc2lEPTB;Mj61NFU1QSEQvF2=	NUHPNYx4W0GQR1XS
Mo-T	NVKxXI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTITWM2OD1{LkWwPVI4KM7:TR?=	NWnvNZhHW0GQR1XS
CCRF-CEM	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLYfJRlUUN3ME2yMlU{ODR\|IN88US=>	M{PFT3NCVkeHUh?=
KU-19-19	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGSwTnVKSzVyPUKuOVM2OTNizszN	M{fHdnNCVkeHUh?=
NCI-H1048	NHvQSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJwNUWwNlUh\|ryP	NFjnWYxUSU6JRWK=
KOSC-2	M1z6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm1W2x4UUN3ME2yMlU3ODd4IN88US=>	NIfqb\|lUSU6JRWK=
A431	NYHHSIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHKTWM2OD1{LkW2N\|M2KM7:TR?=	NUC5VWp4W0GQR1XS
COR-L23	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\uflJOUUN3ME2yMlU5PTZ4IN88US=>	NYLFc5c5W0GQR1XS
MKN28	NH2zdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{ficWlEPTB;Mj61PVA{PyEQvF2=	NVzIUGQ1W0GQR1XS
22RV1	M1zEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLSZZRKSzVyPUKuOVkzPzRizszN	M{m5OHNCVkeHUh?=
ABC-1	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LkRmlEPTB;Mj62NFQ3KM7:TR?=	NFvKZmtUSU6JRWK=
NCI-H2126	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\sN\|NKSzVyPUKuOlA6QDRizszN	NITZboRUSU6JRWK=
DoTc2-4510	NXvMdWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLheGhLUUN3ME2yMlYzOTh3IN88US=>	NXLxNFRkW0GQR1XS
SCC-4	M2r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwNkOwNVIh\|ryP	MYHTRW5ITVJ?
NCI-H661	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHwZVRKSzVyPUKuOlQxQDVizszN	MUPTRW5ITVJ?
RPMI-2650	NIHScWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTJwNkSxOFMh\|ryP	NVruTVBHW0GQR1XS
NCI-H510A	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXwSFVuUUN3ME2yMlY1PDJ4IN88US=>	MU\TRW5ITVJ?
BPH-1	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJwNkW4OUDPxE1?	MnX5V2FPT0WU
M14	M1z2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rXO2lEPTB;Mj62Olk6OyEQvF2=	M4XsZnNCVkeHUh?=
G-402	NULtcFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XV[WlEPTB;Mj63NFQ2OSEQvF2=	M3PyZXNCVkeHUh?=
AsPC-1	M4rMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjwSotKSzVyPUKuO\|EyPyEQvF2=	NX7wd5FQW0GQR1XS
NB12	NULtbHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlyyTWM2OD1{LkexO\|Eh\|ryP	MWPTRW5ITVJ?
SK-HEP-1	NIOz[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7TU5lKSzVyPUKuO\|Q{QTFizszN	MoLuV2FPT0WU
U-266	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2m3SGlEPTB;Mj63O\|EzOSEQvF2=	NUXN[WdrW0GQR1XS
AM-38	NGnZNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TEfWlEPTB;Mj63O\|M2PSEQvF2=	M4\qRnNCVkeHUh?=
PC-14	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PlZ2lEPTB;Mj64NFUyKM7:TR?=	MWDTRW5ITVJ?
EGI-1	NX[2OJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\IRoRKSzVyPUKuPFE4PDNizszN	NX3NNWZxW0GQR1XS
LS-411N	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLrUGc4UUN3ME2yMlgzOzNizszN	NH;oUVJUSU6JRWK=
BFTC-905	M3LNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnHTWM2OD1{Lki1OVI{KM7:TR?=	M1j6SXNCVkeHUh?=
CaR-1	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XvR2lEPTB;Mj64OkDPxE1?	MlrMV2FPT0WU
NCI-H292	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFznPYxKSzVyPUKuPFY2QTZizszN	M2DOSnNCVkeHUh?=
8305C	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PlbGlEPTB;Mj64OlY1PSEQvF2=	MULTRW5ITVJ?
SNU-449	NFfYOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu2bGV6UUN3ME2yMlg6OTh{IN88US=>	M33nSHNCVkeHUh?=
LCLC-103H	M4nUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\UXmlEPTB;Mj65NFQ{QCEQvF2=	NGO2dHNUSU6JRWK=
SW1573	NGD3ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDkXFBKSzVyPUKuPVYxQDJizszN	M2nTfnNCVkeHUh?=
MLMA	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGOwSW9KSzVyPUKuPVY4OTdizszN	M3rOb3NCVkeHUh?=
NCI-H1355	M1f3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3K4VmlEPTB;Mz6wNFc6PiEQvF2=	MlKzV2FPT0WU
RMG-I	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTNwMEK1PVIh\|ryP	MUHTRW5ITVJ?
BB65-RCC	NVjXTZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fY[GlEPTB;Mz6wN\|MyPCEQvF2=	NWTxTVdYW0GQR1XS
PC-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPmXXpKSzVyPUOuNFM5PzRizszN	Ml;sV2FPT0WU
SF268	NHnnTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPENG9KSzVyPUOuNFQ2OjNizszN	MmG1V2FPT0WU
NCI-H810	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTNwMES4NlMh\|ryP	NVrNXpE3W0GQR1XS
MEG-01	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTNwME[xOlQh\|ryP	NHvEO45USU6JRWK=
SW13	M1HsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vBemlEPTB;Mz6wO\|g1PyEQvF2=	NGjaR2xUSU6JRWK=
RH-1	M2K2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTNwMUCyO\|gh\|ryP	NYPQNJJFW0GQR1XS
GT3TKB	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnafYRbUUN3ME2zMlEyOjh\|IN88US=>	NHLwNXRUSU6JRWK=
TK10	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknnTWM2OD1\|LkGzO\|I1KM7:TR?=	NYq3XVU4W0GQR1XS
T-24	NH3aWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{npcGlEPTB;Mz6xOVA4KM7:TR?=	NWXNdY11W0GQR1XS
A498	M2jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3mxSGlEPTB;Mz6yNFg4OSEQvF2=	MV7TRW5ITVJ?
GR-ST	M1Tm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLvTWM2OD1\|LkKyNVM6KM7:TR?=	M17WPHNCVkeHUh?=
LB2518-MEL	M1LlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnhVndKSzVyPUOuNlI{QThizszN	MlTTV2FPT0WU
T47D	NEnyd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\kTWM2OD1\|LkKzOlI4KM7:TR?=	M17nSHNCVkeHUh?=
NCI-H1651	NWjyXJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTNwMkS2OFQh\|ryP	NHrifVRUSU6JRWK=
EC-GI-10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPUUmZEUUN3ME2zMlI3OTV\|IN88US=>	MmnKV2FPT0WU
HT-29	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHzTI1zUUN3ME2zMlI3PjF2IN88US=>	MlTLV2FPT0WU
GI-ME-N	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLrTWM2OD1\|LkK5OVEyKM7:TR?=	NFjvVWRUSU6JRWK=
SW756	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLwUFZKSzVyPUOuNlk3OjlizszN	MoOzV2FPT0WU
RKO	NGHTWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTNwM{C3OVch\|ryP	M{Cy[HNCVkeHUh?=
NCI-H1563	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zXfmlEPTB;Mz6zN\|AyQCEQvF2=	MXPTRW5ITVJ?
DJM-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DiO2lEPTB;Mz6zO\|Y4PCEQvF2=	M370eHNCVkeHUh?=
L-428	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNwNECwOFUh\|ryP	M1u4ZnNCVkeHUh?=
NCI-H2122	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTNwNEGzNVIh\|ryP	MUDTRW5ITVJ?
Ca-Ski	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTZS2RKSzVyPUOuOFU1OyEQvF2=	NVHVPGsyW0GQR1XS
639-V	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn1N4dtUUN3ME2zMlQ3ODV5IN88US=>	NWG1cFlyW0GQR1XS
SW1116	NFLPVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fu[2lEPTB;Mz60OlI3QSEQvF2=	NFXzXolUSU6JRWK=
DMS-114	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTaRZNGUUN3ME2zMlQ4ODZ4IN88US=>	NIrKVoVUSU6JRWK=
MZ2-MEL	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LK[GlEPTB;Mz60O\|Y5OSEQvF2=	NHGzV29USU6JRWK=
COLO-829	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf1TWM2OD1\|LkWwNFc{KM7:TR?=	M4C3VnNCVkeHUh?=
J82	M{HoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTNwNUC1O{DPxE1?	NXu2XohpW0GQR1XS
EW-13	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzFTWM2OD1\|LkWyOVEh\|ryP	NVTzNmdoW0GQR1XS
RXF393	NW[0SW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP5elNKSzVyPUOuOVMzQTRizszN	NVLz[It1W0GQR1XS
CAL-62	M4\JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnYXHBKSzVyPUOuOVQ2OTRizszN	Mo\EV2FPT0WU
OCUB-M	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTNwNUS2OlUh\|ryP	MoTJV2FPT0WU
BT-474	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnGSo0zUUN3ME2zMlY{OzFizszN	MkjQV2FPT0WU
KYSE-180	NHXCPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PxS2lEPTB;Mz62N\|M4OiEQvF2=	NXHVbnY4W0GQR1XS
NCI-H650	M{iyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3:2fGlEPTB;Mz62OFI5PyEQvF2=	M3\uW3NCVkeHUh?=
Detroit562	NYnENZJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnhbGlKSzVyPUOuOlUxOjJizszN	NIK1e2hUSU6JRWK=
SW48	NFr6fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTNwNkW2OVch\|ryP	M3\XT3NCVkeHUh?=
KYSE-450	NHe4NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvVTWM2OD1\|Lk[4OVgzKM7:TR?=	MUnTRW5ITVJ?
KYSE-510	M1PX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHqTWM2OD1\|LkeyNVgyKM7:TR?=	NV7lZlBtW0GQR1XS
GP5d	NGDHUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4L0TWlEPTB;Mz63Nlk2KM7:TR?=	M4OyT3NCVkeHUh?=
RPMI-7951	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHU[FBsUUN3ME2zMlc1PzJ\|IN88US=>	MX\TRW5ITVJ?
Becker	NHziSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1W5[GlEPTB;Mz63OVAyOiEQvF2=	MnW3V2FPT0WU
WM-115	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvEOWEyUUN3ME2zMlc5OTl3IN88US=>	NUXHXGJ[W0GQR1XS
G-401	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUL1Oo5KUUN3ME2zMlc6ODh3IN88US=>	MVfTRW5ITVJ?
PANC-08-13	NV;vco9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHFSIRZUUN3ME2zMlc6PjB{IN88US=>	MUfTRW5ITVJ?
SW982	M4rMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTNwOEC1OVEh\|ryP	NIjVS5BUSU6JRWK=
D-263MG	NUPMfZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTNwOEKwOVEh\|ryP	MYTTRW5ITVJ?
KM-H2	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTNwOEK2NlQh\|ryP	MXPTRW5ITVJ?
SK-MEL-3	M4fGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHBc2tKSzVyPUOuPFI5PDFizszN	MWPTRW5ITVJ?
NCI-H1581	M{m0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;keGlEPTB;Mz64OFQ5QCEQvF2=	MXfTRW5ITVJ?
LS-123	M{LoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TpbGlEPTB;Mz64O\|kxQSEQvF2=	NF60eZFUSU6JRWK=
CAKI-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXLPFhKSzVyPUOuPFkxPTJizszN	NEjnOWJUSU6JRWK=
MEL-JUSO	NUD2N5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnGXJlsUUN3ME2zMlg6OTV\|IN88US=>	NYLIeFkyW0GQR1XS
HCE-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfkcG0zUUN3ME2zMlkyPjZ\|IN88US=>	M2XCeHNCVkeHUh?=
TE-10	NIm5SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPkTWM2OD1\|LkmyNFEh\|ryP	NXj4dVVLW0GQR1XS
OVCAR-4	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTNwOUK4PFkh\|ryP	Mo\oV2FPT0WU
ETK-1	NGrB[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILtS5dKSzVyPUOuPVQ3OzVizszN	NHfifHRUSU6JRWK=
A2780	NGX0cFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP3e4Q2UUN3ME20MlA2QTZ4IN88US=>	NHzMWnRUSU6JRWK=
LU-65	Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1q2NGlEPTB;ND6wO\|Y{OyEQvF2=	M1ziSHNCVkeHUh?=
BHY	NImzPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXtWpBEUUN3ME20MlEzPDl3IN88US=>	NEDVbplUSU6JRWK=
COR-L105	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzBUnZKSzVyPUSuNVMxPTFizszN	MUHTRW5ITVJ?
CAL-12T	M1zON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTRwMUOxNFMh\|ryP	M1fHXHNCVkeHUh?=
SCH	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTRwMUW3OFMh\|ryP	MnntV2FPT0WU
CW-2	M1rDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7SR2ZtUUN3ME20MlE6ODBzIN88US=>	MUfTRW5ITVJ?
HCC1806	MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\DdmlEPTB;ND6yNFMyOiEQvF2=	MoGyV2FPT0WU
KP-N-YN	NFr4dI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXCbYhKSzVyPUSuNlA6OjdizszN	M33ldHNCVkeHUh?=
T98G	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fxcGlEPTB;ND6yNlE2PyEQvF2=	MV\TRW5ITVJ?
CAL-54	NW\CbpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXDVGFwUUN3ME20MlIzOzhzIN88US=>	NYDJPGJoW0GQR1XS
CAL-33	NXu3UIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYP6cYhPUUN3ME20MlI{ODZ2IN88US=>	NWDMZmk5W0GQR1XS
SNU-C2B	NYHzW3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTqTWM2OD12LkK0O\|Y6KM7:TR?=	MkHoV2FPT0WU
NUGC-3	NHrQVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHX1fG1KSzVyPUSuNlU2ODVizszN	M2\1dnNCVkeHUh?=
DOK	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v3PWlEPTB;ND6yOlU6OyEQvF2=	NFzIUVJUSU6JRWK=
MMAC-SF	NGn1S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M123bGlEPTB;ND6yOlg2QSEQvF2=	MUTTRW5ITVJ?
KYSE-70	M2TsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTRwMkmzOEDPxE1?	NWnzfo92W0GQR1XS
A204	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLTNHZ2UUN3ME20MlM2QDB\|IN88US=>	NXjwUZRVW0GQR1XS
SCC-25	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOycYVjUUN3ME20MlM2QDF7IN88US=>	NV;Nc3RpW0GQR1XS
EPLC-272H	M1zSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELQVmFKSzVyPUSuN\|g6PSEQvF2=	M37PfHNCVkeHUh?=
CAL-120	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\mS2xKUUN3ME20MlM5QTl{IN88US=>	MULTRW5ITVJ?
LS-513	NHPGNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTRwNEKxPVgh\|ryP	NEPYZ5FUSU6JRWK=
CAPAN-1	NF\FUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUKwXohQUUN3ME20MlQzOzh{IN88US=>	NFjke\|NUSU6JRWK=
ESS-1	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTRwNEK3NlQh\|ryP	M1LqcHNCVkeHUh?=
GMS-10	NVq3WnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W4VWlEPTB;ND60NlgyQSEQvF2=	Mm\SV2FPT0WU
NCI-N87	MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3qNIJKSzVyPUSuOVA5PjhizszN	MnLyV2FPT0WU
HMV-II	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfMN2hKSzVyPUSuOVE4OyEQvF2=	NYHOSVhzW0GQR1XS
COLO-741	M2\QS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fPSGlEPTB;ND61OVk6PCEQvF2=	MXTTRW5ITVJ?
MKN45	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HmNGlEPTB;ND61O\|c{OiEQvF2=	NYjjRll5W0GQR1XS
OAW-28	M2TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTRwNUizPVgh\|ryP	NULL[VVLW0GQR1XS
OCI-AML2	NXjRRYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7tTJd7UUN3ME20MlY2OjN6IN88US=>	M2Xxb3NCVkeHUh?=
MDA-MB-231	NVjpZWlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTRwN{CyOFMh\|ryP	MlPYV2FPT0WU
NCI-H1648	NFnjOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PLO2lEPTB;ND63NlI4OyEQvF2=	NUjYTXNDW0GQR1XS
NCI-H1792	NVjmR2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTRwN{[xNFch\|ryP	Mnf4V2FPT0WU
GCIY	NH36fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDCTWM2OD12Lke3OFI1KM7:TR?=	M{nDOHNCVkeHUh?=
Hs-578-T	NFXTUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\sTYNCUUN3ME20Mlc4PjV3IN88US=>	MkLjV2FPT0WU
SW962	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f4TmlEPTB;ND63PFAyOSEQvF2=	NF[0[\|NUSU6JRWK=
NCI-H630	M4i2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETJcopKSzVyPUSuO\|gxQDFizszN	M32yVXNCVkeHUh?=
786-0	M1TL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXsNGtKSzVyPUSuO\|g4PzNizszN	M2iwXHNCVkeHUh?=
FTC-133	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTRwN{myOlMh\|ryP	MX;TRW5ITVJ?
BT-20	NE\zWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXZTWM2OD12Lke5OFI6KM7:TR?=	Mo\qV2FPT0WU
Mewo	NVW5bJZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjYTWM2OD12LkixO\|Q4KM7:TR?=	MmnJV2FPT0WU
SW780	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGThZ4xKSzVyPUSuPFU4PjZizszN	NHPzfFRUSU6JRWK=
OE33	M4jvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPxTWM2OD12Lki3O\|E{KM7:TR?=	MV7TRW5ITVJ?
HCC1569	NVHhZVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn36TWM2OD12Lki4OFU5KM7:TR?=	NIWwVmdUSU6JRWK=
TE-6	NFrRN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnVPWxKSzVyPUSuPVM6PzdizszN	M4DkWHNCVkeHUh?=
SK-N-FI	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXGxbW5JUUN3ME20Mlk1PDJzIN88US=>	MWLTRW5ITVJ?
PANC-03-27	NWDTUlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO2W3hKSzVyPUSuPVk6PjJizszN	NIixfHNUSU6JRWK=
MCF7	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTVwMEC3N\|gh\|ryP	NEe1dFVUSU6JRWK=
UACC-257	NHL5RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPweG1KSzVyPUWuNFI5PDVizszN	NFH5RWhUSU6JRWK=
SW1088	M3nMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzBdFIzUUN3ME21MlAzQTR2IN88US=>	M1G3XnNCVkeHUh?=
A704	NFnTRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTVwMEOwOkDPxE1?	NWTkZWt4W0GQR1XS
A2058	M3HYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHWbVRpUUN3ME21MlA2QTB6IN88US=>	MUjTRW5ITVJ?
Calu-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofyTWM2OD13LkC2OFUzKM7:TR?=	M13CO3NCVkeHUh?=
RERF-LC-MS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LTTGlEPTB;NT6wOlkxOyEQvF2=	M3ywVnNCVkeHUh?=
AU565	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTVwMEm3NFIh\|ryP	MYHTRW5ITVJ?
DMS-79	NGK3bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfRfZFKSzVyPUWuNVM5QDNizszN	MVLTRW5ITVJ?
DK-MG	NXPYdHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmG3TWM2OD13LkG4OFM5KM7:TR?=	MVzTRW5ITVJ?
HuCCT1	NFjL[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Sw[mlEPTB;NT6yN\|g2PiEQvF2=	MUnTRW5ITVJ?
HT-144	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjkTWM2OD13LkK0PVg4KM7:TR?=	NEnCZopUSU6JRWK=
M059J	M2jhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvCNpVKSzVyPUWuNlU4PiEQvF2=	NIDXd4hUSU6JRWK=
COLO-792	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW5Z2t6UUN3ME21MlI3OzV4IN88US=>	NH3GbVlUSU6JRWK=
SF539	NYLaUpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTpTWM2OD13LkK2OlMzKM7:TR?=	MmDpV2FPT0WU
SK-UT-1	NGDYeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTVwMke3OVEh\|ryP	MnLJV2FPT0WU
NCI-H1703	M3X3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvxfJloUUN3ME21MlM2QDJ4IN88US=>	NF;KN41USU6JRWK=
SW837	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrTbnBKSzVyPUWuN\|c5PzhizszN	MoTzV2FPT0WU
U251	M2[0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjVR5hbUUN3ME21MlM6ODl4IN88US=>	Mom3V2FPT0WU
SW1710	M1vkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILFRmlKSzVyPUWuOFE2PTRizszN	MWXTRW5ITVJ?
NCI-H1299	NVjnd2ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTVwNE[zN\|Uh\|ryP	NHPzV4xUSU6JRWK=
RVH-421	M2nOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTVwNEm5NFgh\|ryP	M3nvNnNCVkeHUh?=
UM-UC-3	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLYeHhKSzVyPUWuOlI3PTFizszN	NXH6TG5OW0GQR1XS
MDA-MB-175-VII	M2jZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTVwNkSwOFEh\|ryP	NVfZfJBOW0GQR1XS
KYSE-270	NVTPeWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TUTmlEPTB;NT62OlA{OSEQvF2=	NUHjRnp5W0GQR1XS
COLO-668	M1y5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDoTFRKSzVyPUWuO\|E{OiEQvF2=	NVXEd5lsW0GQR1XS
LN-405	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;hd5k2UUN3ME21Mlc{ODh3IN88US=>	MV7TRW5ITVJ?
HT-1376	NFq3[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\scXZ6UUN3ME21Mlc5ODV{IN88US=>	NEnHSJlUSU6JRWK=
769-P	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnW0TWM2OD13Lki2O\|E5KM7:TR?=	MkXXV2FPT0WU
HuP-T3	M3XmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTVwOEi2O\|ch\|ryP	MVzTRW5ITVJ?
MDA-MB-415	NGL5NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFO2d3JKSzVyPUWuPVIyOzlizszN	MYPTRW5ITVJ?
MKN7	M4DDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTVwOUi4JO69VQ>?	MV3TRW5ITVJ?
KS-1	NH;DeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\GWHpKSzVyPUWuPVg5OzZizszN	M1;SR3NCVkeHUh?=
647-V	M3\rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXv[nJHUUN3ME21Mlk6OTR6IN88US=>	NWf5WpQ2W0GQR1XS
COLO-679	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zyOGlEPTB;Nj6wNFI2PSEQvF2=	MlX4V2FPT0WU
AN3-CA	NYTOSGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTZwMEO0OFEh\|ryP	NG\t[FdUSU6JRWK=
C32	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPrdFE2UUN3ME22MlE{ODN2IN88US=>	NFqzUItUSU6JRWK=
KM12	NYL5OIp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjTNXZKSzVyPU[uNlQxQTlizszN	MmnlV2FPT0WU
KINGS-1	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M133cGlEPTB;Nj6yOlE2OiEQvF2=	MXfTRW5ITVJ?
KYSE-410	NFrtWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHi4[ItKSzVyPU[uN\|A3PDVizszN	NYezWYw4W0GQR1XS
HPAF-II	NXuxfWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILQfpJKSzVyPU[uN\|U1QCEQvF2=	Ml;OV2FPT0WU
LAN-6	NHP3VnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFO5UWtKSzVyPU[uOFk3OzFizszN	Mmj5V2FPT0WU
LU-99A	M4X4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX22XmtwUUN3ME22MlU2QTh7IN88US=>	NV\lZ21{W0GQR1XS
SJSA-1	NFHjTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTZUIJkUUN3ME22MlU3OzR5IN88US=>	NXvObG5zW0GQR1XS
MSTO-211H	NWLjU4RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j0R2lEPTB;Nj63NlI{OyEQvF2=	MVvTRW5ITVJ?
SW900	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTZwN{[yNlEh\|ryP	MnfsV2FPT0WU
LNCaP-Clone-FGC	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTZwOEC0NFMh\|ryP	NEThT2lUSU6JRWK=
OMC-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofKTWM2OD14Lki1OFAzKM7:TR?=	NH\KXGdUSU6JRWK=
IST-MEL1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPqTWM2OD14Lki5OlY6KM7:TR?=	M3fvXXNCVkeHUh?=
TE-9	NHX0THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLKTWM2OD14Lki5PFQ4KM7:TR?=	M3jybnNCVkeHUh?=
NCI-H2030	M4rnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL6TWM2OD14LkmxNlI3KM7:TR?=	M4HiNHNCVkeHUh?=
BFTC-909	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnDW3RSUUN3ME23MlAxPjRzIN88US=>	NVjxW5lCW0GQR1XS
NCI-SNU-5	NULX[oo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjJRmxKSzVyPUeuNFIyPTlizszN	M{KzfnNCVkeHUh?=
TE-5	M2T4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojSTWM2OD15LkCyPFgyKM7:TR?=	M3m3ZnNCVkeHUh?=
SK-MES-1	NHnPUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XNSWlEPTB;Nz6wOVQzPyEQvF2=	Mo\NV2FPT0WU
SHP-77	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXxZ3VKSzVyPUeuNVM6PTJizszN	MY\TRW5ITVJ?
NCI-H1623	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLFTWM2OD15LkG0NFczKM7:TR?=	MWfTRW5ITVJ?
TE-11	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\WUmNKSzVyPUeuNVUyQDRizszN	NV7heGJ{W0GQR1XS
EKVX	M2Tsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTdwMUmyOlch\|ryP	M1fVbHNCVkeHUh?=
OVCAR-3	NV;jOm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXwdplQUUN3ME23MlIyOTN\|IN88US=>	MVTTRW5ITVJ?
C3A	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7KN4dKSzVyPUeuN\|Q2OiEQvF2=	NFTkcIpUSU6JRWK=
CFPAC-1	NEPtbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTdwM{[yNlIh\|ryP	MYjTRW5ITVJ?
MG-63	NYfC[YFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\EeolCUUN3ME23MlQyQDR7IN88US=>	MlLHV2FPT0WU
KYSE-140	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDOblJiUUN3ME23MlQ1ODZzIN88US=>	MonBV2FPT0WU
MPP-89	M1GyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH61XFdKSzVyPUeuOVk4OjlizszN	MYPTRW5ITVJ?
COLO-824	NHTjR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPrTWM2OD15LkeyPFY{KM7:TR?=	M{XGWnNCVkeHUh?=
SiHa	NIr3[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK2N3ZKSzVyPUeuPFM4ODdizszN	MWfTRW5ITVJ?
SNU-387	M1zIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXXSZFKSzVyPUeuPFU{PDdizszN	MlfYV2FPT0WU
A172	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULqemxvUUN3ME23Mlg3OTd{IN88US=>	MlXDV2FPT0WU
COLO-680N	NEnIb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TC[2lEPTB;Nz65NVc{KM7:TR?=	Mn7qV2FPT0WU
HCC1395	NX7HRmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRThwMEW0OVIh\|ryP	NGrp[GRUSU6JRWK=
NCI-H28	M1HOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXmy[IZkUUN3ME24MlA2QTZ\|IN88US=>	NU[zV\|J2W0GQR1XS
LC-2-ad	NV3UdWNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDqTWM2OD16LkKxPVM4KM7:TR?=	MYjTRW5ITVJ?
S-117	M{TtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRThwMkWzOVMh\|ryP	NYnseldRW0GQR1XS
NCI-H1838	NGG5TlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMZmFKSzVyPUiuNlU4QDFizszN	M2qxPXNCVkeHUh?=
PANC-10-05	NWDyS4NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjMTWM2OD16LkO3NFQ4KM7:TR?=	M2L2TnNCVkeHUh?=
KALS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LjXWlEPTB;OD61NFkzQCEQvF2=	M2TkS3NCVkeHUh?=
LS-1034	M3XUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPyRXRNUUN3ME24MlU4PDN5IN88US=>	NV3o[HhHW0GQR1XS
TGBC1TKB	M3Oycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWntSGRLUUN3ME24Mlc{PTN3IN88US=>	M2DGOnNCVkeHUh?=
OE19	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHwTWM2OD16Lke2NlYzKM7:TR?=	M1OzfnNCVkeHUh?=
D-502MG	M1\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnIZVZKSzVyPUiuO\|Y6QTRizszN	NX;GO5RFW0GQR1XS
JEG-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRThwN{i2NVgh\|ryP	MlTRV2FPT0WU
DBTRG-05MG	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r0fmlEPTB;OD64O\|U3PSEQvF2=	NF\1W3JUSU6JRWK=
ME-180	NWHpNXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rlUGlEPTB;OT6wOlczPSEQvF2=	MUHTRW5ITVJ?
NCI-H1573	M{\2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2n4fWlEPTB;OT6xNFU{OiEQvF2=	M1;abnNCVkeHUh?=
HCC2998	Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TrO2lEPTB;OT6xN\|Y5OSEQvF2=	NWDVbpMyW0GQR1XS
ACHN	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXlZpRKSzVyPUmuNlQ6PzVizszN	NUjse3ZqW0GQR1XS
D-392MG	NEe0WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTLTWM2OD17LkK1O\|E2KM7:TR?=	MoXOV2FPT0WU
no-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1K4VGlEPTB;OT6yOlAzQCEQvF2=	MojSV2FPT0WU
KLE	M4TuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTlwM{KyN\|Ih\|ryP	NXXFeGdUW0GQR1XS
Calu-6	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTlwM{e1Nlgh\|ryP	M4rabHNCVkeHUh?=
LB831-BLC	M2Lwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTlwNEWxO\|Eh\|ryP	MoPkV2FPT0WU
SW684	NF6wfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4exWmlEPTB;OT60OlEyPiEQvF2=	MVrTRW5ITVJ?
SH-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvQUXhUUUN3ME25MlQ6OzZ2IN88US=>	NWruUZQ6W0GQR1XS
IST-MES1	M{XnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r2OGlEPTB;OT61NVY1PCEQvF2=	MoL1V2FPT0WU
Saos-2	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrDTWM2OD17LkWyNVk2KM7:TR?=	Mn\uV2FPT0WU
NCI-H2087	M17WNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXmTWM2OD17Lk[3N\|UzKM7:TR?=	MX3TRW5ITVJ?
SCC-9	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;YUmJQUUN3ME25MlcyQDF4IN88US=>	NFzEVI9USU6JRWK=
MFE-280	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK3[\|VKSzVyPUmuO\|I4QDVizszN	M2nmNHNCVkeHUh?=
BEN	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTtNnpDUUN3ME25MlgzOTV7IN88US=>	MVLTRW5ITVJ?
CP50-MEL-B	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTlwOUK0N\|Ih\|ryP	NUm0No9nW0GQR1XS
SK-MEL-28	NV63SXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1voUWlEPTB;MUCuNFE6OyEQvF2=	M{XsW3NCVkeHUh?=
NCI-H2452	NFrZW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\HfoJKSzVyPUGwMlE3KM7:TR?=	NULMb\|E6W0GQR1XS
NCI-H1395	M1TzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3XTWM2OD1zMD6xO\|gh\|ryP	NF25e29USU6JRWK=
NCI-H2052	M2nmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYCxfYVkUUN3ME2xNE4yQDh{IN88US=>	MWfTRW5ITVJ?
A375	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFyLkK0OVIh\|ryP	NWH5NJVWW0GQR1XS
HCC38	NUG3UXpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPrTWM2OD1zMD6zNlIh\|ryP	Ml:3V2FPT0WU
LK-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe5eIFKSzVyPUGwMlQzODhizszN	M4HG[nNCVkeHUh?=
SF126	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHLTWM2OD1zMD60O\|I4KM7:TR?=	MofyV2FPT0WU
SK-MEL-1	NV\SS25iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInvOoZKSzVyPUGwMlc5OzhizszN	NEjGbnVUSU6JRWK=
ACN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTFyLki2O\|kh\|ryP	MVzTRW5ITVJ?
BB30-HNC	NFTofoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2npXmlEPTB;MUCuPFcyOSEQvF2=	M4TzOXNCVkeHUh?=
NCI-H747	M2KxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDtcYJ5UUN3ME2xNE45PzR4IN88US=>	M2L3enNCVkeHUh?=
KYSE-150	M{PrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXDTWM2OD1zMT6wN\|g4KM7:TR?=	NELRRnFUSU6JRWK=
D-247MG	NVvnZW5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DQ[mlEPTB;MUGuNVAxQSEQvF2=	MUXTRW5ITVJ?
BxPC-3	NGnyXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGT3XYxKSzVyPUGxMlM4PDdizszN	Mn;FV2FPT0WU
SK-MEL-30	M1riUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rBO2lEPTB;MUGuOFA4QSEQvF2=	MWHTRW5ITVJ?
CAS-1	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTFzLkSxNFkh\|ryP	MWTTRW5ITVJ?
no-10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFK5cIVKSzVyPUGyMlEzOTdizszN	NYq4bIxzW0GQR1XS
NCI-H2405	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTF{LkKwN\|Yh\|ryP	M{LSb3NCVkeHUh?=
KGN	M{XBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrmTWM2OD1zMj6yPVAyKM7:TR?=	MWTTRW5ITVJ?
BB49-HNC	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PDXGlEPTB;MUKuN\|k2PiEQvF2=	M2HtW3NCVkeHUh?=
NCI-H1693	NFzUd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DRNWlEPTB;MUKuOVgyPiEQvF2=	Mn3EV2FPT0WU
RO82-W-1	NYj5WlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vZR2lEPTB;MUOuNFY1QSEQvF2=	MkjZV2FPT0WU
CAL-85-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3GTWM2OD1zMz60N\|k6KM7:TR?=	NGDLdlJUSU6JRWK=
H-EMC-SS	NHjEN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7ncoY5UUN3ME2xN{46OTB2IN88US=>	MlPqV2FPT0WU
SW1783	NEOwbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF2LkKzPVEh\|ryP	M332cnNCVkeHUh?=
LB771-HNC	NV7WZ4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTO[YZjUUN3ME2xOE41OTlizszN	M4LmcXNCVkeHUh?=
HCC70	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PhNWlEPTB;MUSuOFI{OyEQvF2=	MVvTRW5ITVJ?
KNS-81-FD	NIrITnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fkNmlEPTB;MUSuO\|A1PSEQvF2=	MnfkV2FPT0WU
KYSE-520	NHryWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV74[HJtUUN3ME2xOE46OjdizszN	MnXiV2FPT0WU
TGBC24TKB	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnWzTWM2OD1zND65OVM6KM7:TR?=	MkfPV2FPT0WU
SNB75	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTF3LkC3Nlkh\|ryP	MWTTRW5ITVJ?
SW872	NYDzWlF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHjTWM2OD1zNT6yNlE5KM7:TR?=	MYfTRW5ITVJ?
U031	M{PjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTF3LkiwNlgh\|ryP	M4nnNHNCVkeHUh?=
ChaGo-K-1	NX32RlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPLOGlKSzVyPUG1Mlg{PTlizszN	M{[xTHNCVkeHUh?=
NCI-H441	M2jZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGeyU\|NKSzVyPUG2MlAxOzlizszN	MXPTRW5ITVJ?
TE-12	M{TY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLMbY1LUUN3ME2xOk4yQDd\|IN88US=>	M1jTNXNCVkeHUh?=
NCI-H1755	M{Xuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHWTWM2OD1zNj61O\|Mh\|ryP	NUPScopjW0GQR1XS
KNS-42	M{LuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfvfIRKSzVyPUG2MlY2QDlizszN	NEnxenNUSU6JRWK=
SK-PN-DW	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PpZmlEPTB;MUeuOFIxOSEQvF2=	MX;TRW5ITVJ?
NCI-H226	NEKxXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\tTWM2OD1zNz65N\|Q2KM7:TR?=	NGXsZ2JUSU6JRWK=
K-562	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHmVYRlUUN3ME2xPE43OzF5IN88US=>	NHXoNVRUSU6JRWK=
A388	NIrJdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HEN2lEPTB;MUmuNFMxOyEQvF2=	NGGxVVJUSU6JRWK=
ZR-75-30	M1TZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF61fVdKSzVyPUG5MlA6PjhizszN	NYTGZVM4W0GQR1XS
LU-135	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{C2UmlEPTB;MUmuNlY{PiEQvF2=	MYXTRW5ITVJ?
NCI-H2029	M3Pjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PjPGlEPTB;MUmuOlAzOSEQvF2=	MnLNV2FPT0WU
HT-1197	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HMT2lEPTB;MUmuPVIzPyEQvF2=	MoK1V2FPT0WU
IGR-1	NXzHe4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vwOGlEPTB;MkCuN\|EyPyEQvF2=	NYftZm5jW0GQR1XS
U-87-MG	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f5T2lEPTB;MkCuOlQyOyEQvF2=	MX3TRW5ITVJ?
NCI-H1304	NXTPV3pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJyLke1NFEh\|ryP	M{jPXXNCVkeHUh?=
RCC10RGB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3[5SWlEPTB;MkGuNlgzQSEQvF2=	MorKV2FPT0WU
NCI-H520	NV\rVXprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJ{Lke2NVEh\|ryP	MoXiV2FPT0WU
SK-LU-1	NFPF[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW[5ZXVwUUN3ME2yN{4xPzF6IN88US=>	MnrnV2FPT0WU
UACC-893	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJ\|LkGwN\|gh\|ryP	NIS2RlRUSU6JRWK=
NCI-H2347	NYriXGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrLTWM2OD1{Mz6yOlc1KM7:TR?=	MWXTRW5ITVJ?
U-118-MG	NF;GZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjwSo5KSzVyPUKzMlczOTdizszN	MVnTRW5ITVJ?
NCI-H596	NUnkcIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nSXmlEPTB;MkOuPVA2PSEQvF2=	MmPGV2FPT0WU
MZ1-PC	NYDpUFV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGwTWM2OD1{ND62O\|U6KM7:TR?=	NH\VSWtUSU6JRWK=
SW1417	M4q2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJ3LkK0PVgh\|ryP	MWPTRW5ITVJ?
NCI-H82	M3i3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXye2JKSzVyPUK2MlQzQDhizszN	NVfyenU2W0GQR1XS
COLO-678	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7DepJKSzVyPUK3MlQ6OTlizszN	NInuZoNUSU6JRWK=
KURAMOCHI	NFi1fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P0dmlEPTB;MkiuNVI3KM7:TR?=	M1n0VHNCVkeHUh?=
NCI-H1650	MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfveGIxUUN3ME2zNE4yQTJ2IN88US=>	M3i0[nNCVkeHUh?=
HCC1954	NEPvN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTNzLkO2OlYh\|ryP	MVrTRW5ITVJ?
GAK	M3PCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjyTWM2OD1\|Mj6yOlE3KM7:TR?=	MVPTRW5ITVJ?
YAPC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTN\|Lke2OFgh\|ryP	MWrTRW5ITVJ?
NCI-H2228	NVHpeVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe3b4dmUUN3ME2zOE4{PjB3IN88US=>	Ml\ZV2FPT0WU
VMRC-RCZ	NVLxeZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTN4LkOwNlIh\|ryP	Mn:2V2FPT0WU
NMC-G1	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjKTWM2OD1\|Nz6wOVI6KM7:TR?=	MoH2V2FPT0WU
D-336MG	M4TJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO0eWtKSzVyPUSxMlg1PDJizszN	M1PRV3NCVkeHUh?=
UACC-62	NXnNZlFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\rSlJKSzVyPUSyMlU2ODVizszN	NILYZmFUSU6JRWK=
C-33-A	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXNSY9KSzVyPUS1MlMzPTZizszN	NV[4[GV4W0GQR1XS
HCC1937	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHsSYE5UUN3ME20O{4yQTV6IN88US=>	NUDldYpnW0GQR1XS
HDLM-2	M{PtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDxcI5KUUN3ME20O{4zOjh5IN88US=>	MnrxV2FPT0WU
NCI-H727	NVy4dlNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTR5LkK0OVEh\|ryP	MV3TRW5ITVJ?
NY	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3mTWM2OD12OT6zPVA5KM7:TR?=	NXviUIlnW0GQR1XS
NCI-H2291	M3rnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnFTWM2OD12OT64N\|AyKM7:TR?=	M33CN3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MK0683
Smiles	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Withdrawn	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)